WO2002006264A1 - Inhibiteurs de plaques riches en lipide - Google Patents
Inhibiteurs de plaques riches en lipide Download PDFInfo
- Publication number
- WO2002006264A1 WO2002006264A1 PCT/JP2001/006070 JP0106070W WO0206264A1 WO 2002006264 A1 WO2002006264 A1 WO 2002006264A1 JP 0106070 W JP0106070 W JP 0106070W WO 0206264 A1 WO0206264 A1 WO 0206264A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituent
- ring
- salt
- compound
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 54
- 239000003112 inhibitor Substances 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 232
- 150000003839 salts Chemical class 0.000 claims abstract description 167
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 58
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 44
- 125000003118 aryl group Chemical group 0.000 claims abstract description 35
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 15
- 239000000470 constituent Substances 0.000 claims abstract description 12
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 20
- 125000001424 substituent group Chemical group 0.000 claims description 256
- 125000000217 alkyl group Chemical group 0.000 claims description 137
- 239000003814 drug Substances 0.000 claims description 125
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 97
- 150000002430 hydrocarbons Chemical group 0.000 claims description 84
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 70
- 125000005843 halogen group Chemical group 0.000 claims description 67
- 125000003277 amino group Chemical group 0.000 claims description 65
- 239000003795 chemical substances by application Substances 0.000 claims description 64
- 238000006243 chemical reaction Methods 0.000 claims description 62
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 60
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 54
- 125000004043 oxo group Chemical group O=* 0.000 claims description 41
- 229910052757 nitrogen Inorganic materials 0.000 claims description 39
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 38
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 125000004432 carbon atom Chemical group C* 0.000 claims description 33
- 241000124008 Mammalia Species 0.000 claims description 32
- 229910052801 chlorine Inorganic materials 0.000 claims description 29
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 27
- 229930195733 hydrocarbon Natural products 0.000 claims description 26
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 125000004429 atom Chemical group 0.000 claims description 23
- 229940002612 prodrug Drugs 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 239000004215 Carbon black (E152) Substances 0.000 claims description 18
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 15
- 125000002541 furyl group Chemical group 0.000 claims description 15
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 13
- 208000007814 Unstable Angina Diseases 0.000 claims description 13
- 230000002093 peripheral effect Effects 0.000 claims description 13
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 12
- 208000021328 arterial occlusion Diseases 0.000 claims description 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 12
- 230000000069 prophylactic effect Effects 0.000 claims description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 10
- 206010002388 Angina unstable Diseases 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 9
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 7
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 230000003143 atherosclerotic effect Effects 0.000 claims description 4
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
- 230000001603 reducing effect Effects 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- 229910052720 vanadium Inorganic materials 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 150000001555 benzenes Chemical group 0.000 claims 2
- CHHVIZQASRTMGS-UHFFFAOYSA-N n-[4-fluoro-2-(trifluoromethyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1C(F)(F)F CHHVIZQASRTMGS-UHFFFAOYSA-N 0.000 claims 2
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical group C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical group OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- -1 cholesterol Chemical class 0.000 description 358
- 235000002639 sodium chloride Nutrition 0.000 description 143
- 229940079593 drug Drugs 0.000 description 107
- 238000002360 preparation method Methods 0.000 description 63
- 125000003545 alkoxy group Chemical group 0.000 description 59
- 239000002904 solvent Substances 0.000 description 55
- 239000002253 acid Substances 0.000 description 37
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 37
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 239000011248 coating agent Substances 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 239000002585 base Substances 0.000 description 28
- 125000005842 heteroatom Chemical group 0.000 description 28
- 150000001721 carbon Chemical group 0.000 description 26
- 239000000546 pharmaceutical excipient Substances 0.000 description 26
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 25
- 239000000460 chlorine Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 23
- 229910052731 fluorine Inorganic materials 0.000 description 23
- 229910052717 sulfur Inorganic materials 0.000 description 23
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 22
- 125000004122 cyclic group Chemical group 0.000 description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 22
- 239000011737 fluorine Substances 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 21
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 229910052736 halogen Inorganic materials 0.000 description 20
- 150000002367 halogens Chemical class 0.000 description 20
- 229920000642 polymer Polymers 0.000 description 20
- 125000004076 pyridyl group Chemical group 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 125000004434 sulfur atom Chemical group 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000000576 coating method Methods 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 17
- 125000004414 alkyl thio group Chemical group 0.000 description 17
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 17
- 229910052794 bromium Inorganic materials 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- 229910052708 sodium Inorganic materials 0.000 description 17
- 229940083542 sodium Drugs 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000000654 additive Substances 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 229920002472 Starch Polymers 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 210000000214 mouth Anatomy 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 239000001301 oxygen Chemical group 0.000 description 15
- 125000000714 pyrimidinyl group Chemical group 0.000 description 15
- 239000008107 starch Substances 0.000 description 15
- 229940032147 starch Drugs 0.000 description 15
- 235000019698 starch Nutrition 0.000 description 15
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 15
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 14
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 14
- 125000003282 alkyl amino group Chemical group 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 229920002678 cellulose Polymers 0.000 description 14
- 239000000314 lubricant Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- 125000004430 oxygen atom Chemical group O* 0.000 description 14
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- 235000010980 cellulose Nutrition 0.000 description 13
- 239000001913 cellulose Substances 0.000 description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 13
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 239000003381 stabilizer Substances 0.000 description 13
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229930006000 Sucrose Natural products 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
- 229910052783 alkali metal Inorganic materials 0.000 description 12
- 239000003405 delayed action preparation Substances 0.000 description 12
- 239000007884 disintegrant Substances 0.000 description 12
- 239000008187 granular material Substances 0.000 description 12
- 125000001624 naphthyl group Chemical group 0.000 description 12
- 229960004793 sucrose Drugs 0.000 description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 11
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- 235000010355 mannitol Nutrition 0.000 description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
- 125000003342 alkenyl group Chemical group 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 10
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 10
- 239000011593 sulfur Chemical group 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 125000000335 thiazolyl group Chemical group 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 125000002757 morpholinyl group Chemical group 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000005858 Triflumizole Substances 0.000 description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 8
- 208000026106 cerebrovascular disease Diseases 0.000 description 8
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000002934 diuretic Substances 0.000 description 8
- 230000032050 esterification Effects 0.000 description 8
- 238000005886 esterification reaction Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 125000002883 imidazolyl group Chemical group 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 229960001375 lactose Drugs 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 229960001855 mannitol Drugs 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- HSMVPDGQOIQYSR-KGENOOAVSA-N triflumizole Chemical compound C1=CN=CN1C(/COCCC)=N/C1=CC=C(Cl)C=C1C(F)(F)F HSMVPDGQOIQYSR-KGENOOAVSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- INOFNEWQYCGESC-UHFFFAOYSA-N acetic acid;chromen-2-one Chemical class CC(O)=O.C1=CC=C2OC(=O)C=CC2=C1 INOFNEWQYCGESC-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 150000001924 cycloalkanes Chemical class 0.000 description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000001530 fumaric acid Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 229960001031 glucose Drugs 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000003223 protective agent Substances 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 125000000168 pyrrolyl group Chemical group 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 6
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 6
- 150000008065 acid anhydrides Chemical class 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 6
- 229940105329 carboxymethylcellulose Drugs 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 229940099112 cornstarch Drugs 0.000 description 6
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 235000019425 dextrin Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002170 ethers Chemical class 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 239000011976 maleic acid Substances 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 229960002900 methylcellulose Drugs 0.000 description 6
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000006190 sub-lingual tablet Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- 239000011975 tartaric acid Substances 0.000 description 6
- 235000002906 tartaric acid Nutrition 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 5
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 5
- 229920000148 Polycarbophil calcium Polymers 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 5
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 235000013877 carbamide Nutrition 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 150000001925 cycloalkenes Chemical class 0.000 description 5
- 229940030606 diuretics Drugs 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 5
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 125000002971 oxazolyl group Chemical group 0.000 description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 229940098466 sublingual tablet Drugs 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- 150000004982 aromatic amines Chemical class 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- 238000007887 coronary angioplasty Methods 0.000 description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 4
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical group C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000012052 hydrophilic carrier Substances 0.000 description 4
- 238000004898 kneading Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229950005134 polycarbophil Drugs 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 229960001860 salicylate Drugs 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000001384 succinic acid Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000012929 tonicity agent Substances 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 150000003672 ureas Chemical class 0.000 description 4
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 3
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 3
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical group C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 3
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 3
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical group C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 3
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 3
- RVGLUKRYMXEQAH-UHFFFAOYSA-N 3,3-dimethyloxetane Chemical compound CC1(C)COC1 RVGLUKRYMXEQAH-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 241001024304 Mino Species 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- QDPOOGQUCJJZAO-FCXRPNKRSA-N [(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QDPOOGQUCJJZAO-FCXRPNKRSA-N 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000003973 alkyl amines Chemical class 0.000 description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940127003 anti-diabetic drug Drugs 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 description 3
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 125000004956 cyclohexylene group Chemical group 0.000 description 3
- GPTJTTCOVDDHER-UHFFFAOYSA-N cyclononane Chemical compound C1CCCCCCCC1 GPTJTTCOVDDHER-UHFFFAOYSA-N 0.000 description 3
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 3
- 239000004914 cyclooctane Substances 0.000 description 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 3
- 229960002433 cysteine Drugs 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 229950007304 denopamine Drugs 0.000 description 3
- VHSBBVZJABQOSG-MRXNPFEDSA-N denopamine Chemical compound C1=C(OC)C(OC)=CC=C1CCNC[C@@H](O)C1=CC=C(O)C=C1 VHSBBVZJABQOSG-MRXNPFEDSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical group C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 150000008282 halocarbons Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 3
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- 229960004940 sulpiride Drugs 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000002769 thiazolinyl group Chemical group 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- 239000005526 vasoconstrictor agent Substances 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical group C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical group C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- PWYJJQYPSILKKB-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate;hydrochloride Chemical compound Cl.C1CCCC1(O)C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 PWYJJQYPSILKKB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 125000005999 2-bromoethyl group Chemical group 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- YKGYIDJEEQRWQH-UHFFFAOYSA-N 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic acid ethyl ester Chemical compound CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)N)C=C1 YKGYIDJEEQRWQH-UHFFFAOYSA-N 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical group C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 2
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- NFQIAEMCQGTTIR-UHFFFAOYSA-N Repirinast Chemical compound C12=CC=C(C)C(C)=C2NC(=O)C2=C1OC(C(=O)OCCC(C)C)=CC2=O NFQIAEMCQGTTIR-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940023476 agar Drugs 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 2
- 229960003556 aminophylline Drugs 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000003904 antiprotozoal agent Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- HMEDEBAJARCKCT-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=NN1 HMEDEBAJARCKCT-UHFFFAOYSA-N 0.000 description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 125000006251 butylcarbonyl group Chemical group 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 2
- 229960000932 candesartan Drugs 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 2
- 229960003791 cefmenoxime Drugs 0.000 description 2
- 229960001242 cefotiam Drugs 0.000 description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 125000001485 cycloalkadienyl group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical group C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 2
- 229960000648 digitoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KZTYYGOKRVBIMI-UHFFFAOYSA-N diphenyl sulfone Chemical compound C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 KZTYYGOKRVBIMI-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 229950000501 gabexate Drugs 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 229960002491 ibudilast Drugs 0.000 description 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 150000002547 isoxazolines Chemical class 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960004958 ketotifen Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229950008446 melinamide Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 2
- 229960003746 metildigoxin Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960005195 morphine hydrochloride Drugs 0.000 description 2
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- MSXTUBJFNBZPGC-UHFFFAOYSA-N n-[4-oxo-2-(2h-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide;hydrate Chemical compound O.C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1.C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1 MSXTUBJFNBZPGC-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229960005222 phenazone Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 229960004583 pranlukast Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- 229950009147 repirinast Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 229960003090 seratrodast Drugs 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000004059 squalene synthase inhibitor Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 2
- 229960005342 tranilast Drugs 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- NYRVBYLXLHGXDP-UTLKBRERSA-N (1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrate;hydrochloride Chemical compound O.Cl.COC1=C(OC)C(OC)=CC(C[C@H]2C3=CC(O)=C(O)C=C3CCN2)=C1 NYRVBYLXLHGXDP-UTLKBRERSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- AJZJIYUOOJLBAU-CEAXSRTFSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n,n,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 AJZJIYUOOJLBAU-CEAXSRTFSA-N 0.000 description 1
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- BAVDEDVBIHTHJQ-UVJOBNTFSA-N (2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate Chemical compound O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 BAVDEDVBIHTHJQ-UVJOBNTFSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 1
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CDXSAEUWBWZFND-UHFFFAOYSA-N (N-hydroxy-C-methylcarbonimidoyl) 2-cyanoacetate Chemical compound ON=C(C)OC(=O)CC#N CDXSAEUWBWZFND-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- MPQKYZPYCSTMEI-FLZPLBAKSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;dihydrate;hydrochloride Chemical compound O.O.Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 MPQKYZPYCSTMEI-FLZPLBAKSA-N 0.000 description 1
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 1
- ILFIRBGRMCGNOO-UHFFFAOYSA-N 1,1-bis($l^{1}-oxidanyl)ethene Chemical group [O]C([O])=C ILFIRBGRMCGNOO-UHFFFAOYSA-N 0.000 description 1
- LZTSCEYDCZBRCJ-UHFFFAOYSA-N 1,2-dihydro-1,2,4-triazol-3-one Chemical compound OC=1N=CNN=1 LZTSCEYDCZBRCJ-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- XCRAFTGAMMSJLO-UHFFFAOYSA-K 1,5-dimethyl-2-phenylpyrazol-3-one;2-hydroxypropane-1,2,3-tricarboxylate;1,3,7-trimethylpurine-2,6-dione Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.CN1C(C)=CC(=O)N1C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C XCRAFTGAMMSJLO-UHFFFAOYSA-K 0.000 description 1
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- SQUNAWUMZGQQJD-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one Chemical compound C1=CC(CC)=CC=C1C(=O)C(C)CN1CCCCC1 SQUNAWUMZGQQJD-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- RPZOFMHRRHHDPZ-UHFFFAOYSA-N 1-[2-(2-cyanoaziridin-1-yl)propan-2-yl]aziridine-2-carboxamide Chemical compound C1C(C(N)=O)N1C(C)(C)N1CC1C#N RPZOFMHRRHHDPZ-UHFFFAOYSA-N 0.000 description 1
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 description 1
- UUTRFZNTTSPNOY-UHFFFAOYSA-N 1-[3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]-4-piperidin-1-ylpiperidine-4-carboxamide;dihydrochloride Chemical compound [Cl-].[Cl-].C1C[NH+](CCCN2C3=CC(Cl)=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)[NH+]1CCCCC1 UUTRFZNTTSPNOY-UHFFFAOYSA-N 0.000 description 1
- NUBQKPWHXMGDLP-UHFFFAOYSA-N 1-[4-benzyl-2-hydroxy-5-[(2-hydroxy-2,3-dihydro-1h-inden-1-yl)amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.C1CN(CC(O)CC(CC=2C=CC=CC=2)C(=O)NC2C3=CC=CC=C3CC2O)C(C(=O)NC(C)(C)C)CN1CC1=CC=CN=C1 NUBQKPWHXMGDLP-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 1
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- KAHPDQNYPVBHGE-UHFFFAOYSA-N 2-benzofuran-1-carbaldehyde Chemical compound C1=CC=CC2=C(C=O)OC=C21 KAHPDQNYPVBHGE-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- CAFXGFHPOQBGJP-UHFFFAOYSA-N 2-cyano-2-hydroxyiminoacetamide Chemical compound NC(=O)C(=NO)C#N CAFXGFHPOQBGJP-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- SSONCJTVDRSLNK-UHFFFAOYSA-N 2-methylprop-2-enoic acid;hydrochloride Chemical compound Cl.CC(=C)C(O)=O SSONCJTVDRSLNK-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- LPHWCAUEPAUFHZ-UHFFFAOYSA-N 3,6-Dihydropyridine Chemical compound C1C=CCN=C1 LPHWCAUEPAUFHZ-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical group C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 description 1
- WEDKTMOIKOKBSH-UHFFFAOYSA-N 4,5-dihydrothiadiazole Chemical group C1CN=NS1 WEDKTMOIKOKBSH-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- WZBCGBHVFQPVKQ-UHFFFAOYSA-N 4-ethoxy-4-oxobutanoic acid;hydrochloride Chemical compound Cl.CCOC(=O)CCC(O)=O WZBCGBHVFQPVKQ-UHFFFAOYSA-N 0.000 description 1
- RNOVGJWJVRESAA-UHFFFAOYSA-N 4-fluoro-2-(trifluoromethyl)phenol Chemical group OC1=CC=C(F)C=C1C(F)(F)F RNOVGJWJVRESAA-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- FVLQEFBCRZSAQO-UHFFFAOYSA-N 4-phenyl-2h-chromene Chemical compound C=1COC2=CC=CC=C2C=1C1=CC=CC=C1 FVLQEFBCRZSAQO-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-FVUVGDFOSA-N 5,6-trans-vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1/C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-FVUVGDFOSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- JAYNVIPOHJITNS-UHFFFAOYSA-N C(C)C1=C(C(=O)OCCN)C=CC=C1 Chemical compound C(C)C1=C(C(=O)OCCN)C=CC=C1 JAYNVIPOHJITNS-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- GEGJXGRKIZUWCN-UHFFFAOYSA-N CN(C)COC(O)=O Chemical compound CN(C)COC(O)=O GEGJXGRKIZUWCN-UHFFFAOYSA-N 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- XYGSFNHCFFAJPO-UHFFFAOYSA-N Chlophedianol hydrochloride Chemical compound Cl.C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 XYGSFNHCFFAJPO-UHFFFAOYSA-N 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 description 1
- IPOBOOXFSRWSHL-UHFFFAOYSA-N Cibenzoline Chemical compound C=1C=CC=CC=1C1(C=2C=CC=CC=2)CC1C1=NCCN1 IPOBOOXFSRWSHL-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- ZLVMAMIPILWYHQ-INIZCTEOSA-N Docarpamine Chemical compound CCOC(=O)OC1=CC=C(CCNC(=O)[C@H](CCSC)NC(C)=O)C=C1OC(=O)OCC ZLVMAMIPILWYHQ-INIZCTEOSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000277306 Esocidae Species 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 1
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- CEVCTNCUIVEQOY-UHFFFAOYSA-N Fumagillol Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(O)CCC21CO2 CEVCTNCUIVEQOY-UHFFFAOYSA-N 0.000 description 1
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- XDKCGKQHVBOOHC-UHFFFAOYSA-N Haloxazolam Chemical compound FC1=CC=CC=C1C1(C2=CC(Br)=CC=C2NC(=O)C2)N2CCO1 XDKCGKQHVBOOHC-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 229930188389 Lanatoside Natural products 0.000 description 1
- 102100032011 Lanosterol synthase Human genes 0.000 description 1
- 108010059597 Lanosterol synthase Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 229930183998 Lividomycin Natural products 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical compound C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- SIDLZWOQUZRBRU-UHFFFAOYSA-N Methyprylon Chemical compound CCC1(CC)C(=O)NCC(C)C1=O SIDLZWOQUZRBRU-UHFFFAOYSA-N 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 description 1
- VRAHPESAMYMDQI-UHFFFAOYSA-N Nicomol Chemical compound C1CCC(COC(=O)C=2C=NC=CC=2)(COC(=O)C=2C=NC=CC=2)C(O)C1(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 VRAHPESAMYMDQI-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- SHAYBENGXDALFF-UHFFFAOYSA-N Nortriptyline hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2C(=CCC[NH2+]C)C2=CC=CC=C21 SHAYBENGXDALFF-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 241000412169 Peria Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 244000090599 Plantago psyllium Species 0.000 description 1
- 235000010451 Plantago psyllium Nutrition 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
- 101150107341 RERE gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- 229930192786 Sisomicin Natural products 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 1
- 108020003891 Squalene monooxygenase Proteins 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UNZIDPIPYUMVPA-UHFFFAOYSA-M Sulpyrine Chemical compound O.[Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 UNZIDPIPYUMVPA-UHFFFAOYSA-M 0.000 description 1
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 1
- ZCDNRPPFBQDQHR-SSYATKPKSA-N Syrosingopine Chemical compound C1=C(OC)C(OC(=O)OCC)=C(OC)C=C1C(=O)O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@H]2C[C@@H]3C(NC=4C5=CC=C(OC)C=4)=C5CCN3C[C@H]2C1 ZCDNRPPFBQDQHR-SSYATKPKSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical group C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- ZBUVYROEHQQAKL-UHFFFAOYSA-N Tolperisone hydrochloride Chemical compound Cl.C=1C=C(C)C=CC=1C(=O)C(C)CN1CCCCC1 ZBUVYROEHQQAKL-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- YFGQJKBUXPKSAW-ZUDKKNPISA-N [(2r,3r,4s)-6-[(2r,3s,4s)-4-hydroxy-6-[(2r,3s,4s)-4-hydroxy-6-[[(3s,9s,10s,13r,17r)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-y Chemical compound O([C@H]1[C@@H](OC(C)=O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@@H]1CC2[C@]([C@@H]3C(C4(CC[C@@H]([C@@]4(C)CC3)C=3COC(=O)C=3)O)CC2)(C)CC1)C1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O YFGQJKBUXPKSAW-ZUDKKNPISA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- KURZCZMGELAPSV-UHFFFAOYSA-N [Br].[I] Chemical compound [Br].[I] KURZCZMGELAPSV-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- KKLWSPPIRBIEOV-UHFFFAOYSA-N [n'-(n'-butylcarbamimidoyl)carbamimidoyl]azanium;chloride Chemical compound Cl.CCCCN=C(N)N=C(N)N KKLWSPPIRBIEOV-UHFFFAOYSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acenaphthylene Chemical group C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229940062328 actos Drugs 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- NHAQIMXLMCBYFZ-UHFFFAOYSA-N aluminum;sodium Chemical compound [Na+].[Al+3] NHAQIMXLMCBYFZ-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 239000003006 anti-agglomeration agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 210000003293 antilymphocyte serum Anatomy 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229950007556 aranidipine Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 229960004988 azosemide Drugs 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- RDUHXGIIUDVSHR-UHFFFAOYSA-N bamethan Chemical compound CCCCNCC(O)C1=CC=C(O)C=C1 RDUHXGIIUDVSHR-UHFFFAOYSA-N 0.000 description 1
- 229960004162 bamethan Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- RRTCFFFUTAGOSG-UHFFFAOYSA-N benzene;phenol Chemical compound C1=CC=CC=C1.OC1=CC=CC=C1 RRTCFFFUTAGOSG-UHFFFAOYSA-N 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical class OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- UXXXZMDJQLPQPH-UHFFFAOYSA-N bis(2-methylpropyl) carbonate Chemical compound CC(C)COC(=O)OCC(C)C UXXXZMDJQLPQPH-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UCDKONUHZNTQPY-UHFFFAOYSA-N bromhexine hydrochloride Chemical compound Cl.C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N UCDKONUHZNTQPY-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960002467 bunazosin Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095498 calcium polycarbophil Drugs 0.000 description 1
- IPLQYSPEGHNJCQ-UHFFFAOYSA-L calcium;5-amino-2-carboxyphenolate;trihydrate Chemical compound O.O.O.[Ca+2].NC1=CC=C(C(O)=O)C([O-])=C1.NC1=CC=C(C(O)=O)C([O-])=C1 IPLQYSPEGHNJCQ-UHFFFAOYSA-L 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229960005286 carbaryl Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 229950008486 carperitide Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- OGHNVEJMJSYVRP-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2 OGHNVEJMJSYVRP-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- SMSRCGPDNDCXFR-CYWZMYCQSA-N cefbuperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]1(OC)C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 SMSRCGPDNDCXFR-CYWZMYCQSA-N 0.000 description 1
- 229960001817 cefbuperazone Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- JSDXOWVAHXDYCU-VXSYNFHWSA-N cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 description 1
- 229960002025 cefminox Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229960003202 cefsulodin Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 239000003601 chymase inhibitor Substances 0.000 description 1
- 229960004757 cibenzoline Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- JQRZBPFGBRIWSN-YOTVLOEGSA-N cilazapril monohydrate Chemical compound O.C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 JQRZBPFGBRIWSN-YOTVLOEGSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- 229950001534 clocapramine Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960002544 cloperastine Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960003932 cloxazolam Drugs 0.000 description 1
- ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 1
- PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 1
- 229960003771 cocaine hydrochloride Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- UCDHYFZYUGDETN-UHFFFAOYSA-N cyanophosphonic acid Chemical compound OP(O)(=O)C#N UCDHYFZYUGDETN-UHFFFAOYSA-N 0.000 description 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229940018872 dalteparin sodium Drugs 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical class C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001079 dilazep Drugs 0.000 description 1
- VILIWRRWAWKXRW-UHFFFAOYSA-N dilazep dihydrochloride Chemical compound [Cl-].[Cl-].COC1=C(OC)C(OC)=CC(C(=O)OCCC[NH+]2CC[NH+](CCCOC(=O)C=3C=C(OC)C(OC)=C(OC)C=3)CCC2)=C1 VILIWRRWAWKXRW-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 150000005218 dimethyl ethers Chemical class 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 229950006045 docarpamine Drugs 0.000 description 1
- 150000002031 dolichols Chemical class 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 229960002565 eperisone Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- VIBDJEWPNNCFQO-UHFFFAOYSA-N ethane-1,1,2-triol Chemical compound OCC(O)O VIBDJEWPNNCFQO-UHFFFAOYSA-N 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- 229950007164 ethiazide Drugs 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960004404 etizolam Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- SGZRQMALQBXAIQ-UHFFFAOYSA-N fenoterol hydrobromide Chemical compound Br.C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 SGZRQMALQBXAIQ-UHFFFAOYSA-N 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 229960003240 floctafenine Drugs 0.000 description 1
- UHRBTBZOWWGKMK-DOMZBBRYSA-N flomoxef Chemical compound O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 1
- 229960002878 flomoxef Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004930 fludiazepam Drugs 0.000 description 1
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002107 fluvoxamine maleate Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- CEVCTNCUIVEQOY-STXHBLNNSA-N fumagillol Chemical compound C([C@@H](O)[C@H](C1[C@]2(C)[C@H](O2)CC=C(C)C)OC)C[C@@]21CO2 CEVCTNCUIVEQOY-STXHBLNNSA-N 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 239000003457 ganglion blocking agent Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 229960004553 guanabenz Drugs 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 239000002515 guano Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 229950002502 haloxazolam Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- KRQAMFQCSAJCRH-UHFFFAOYSA-N hexobendine Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCCN(C)CCN(C)CCCOC(=O)C=2C=C(OC)C(OC)=C(OC)C=2)=C1 KRQAMFQCSAJCRH-UHFFFAOYSA-N 0.000 description 1
- 229960002212 hexobendine Drugs 0.000 description 1
- 102000056614 human NPPA Human genes 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960002600 icosapent ethyl Drugs 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 150000002468 indanes Chemical class 0.000 description 1
- 229960004243 indinavir sulfate Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002869 intravenous anesthetic agent Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 235000000396 iron Nutrition 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229940018448 isoproterenol hydrochloride Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 229950003076 lividomycin Drugs 0.000 description 1
- DBLVDAUGBTYDFR-SWMBIRFSSA-N lividomycin A Chemical compound O([C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@H]([C@H]1O)O[C@H]1O[C@H]([C@H]([C@H](O)[C@H]1N)O[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)CN)[C@H]1O[C@H](CO)[C@@H](O)C[C@H]1N DBLVDAUGBTYDFR-SWMBIRFSSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- 229960004992 maprotiline hydrochloride Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 229940064748 medrol Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 229960003861 mephenesin Drugs 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 238000006063 methoxycarbonylation reaction Methods 0.000 description 1
- OEHAYUOVELTAPG-UHFFFAOYSA-N methoxyphenamine Chemical compound CNC(C)CC1=CC=CC=C1OC OEHAYUOVELTAPG-UHFFFAOYSA-N 0.000 description 1
- 229960005405 methoxyphenamine Drugs 0.000 description 1
- 229960003739 methyclothiazide Drugs 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229960000316 methyprylon Drugs 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- YNPFMWCWRVTGKJ-UHFFFAOYSA-N mianserin hydrochloride Chemical compound [H+].[Cl-].C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 YNPFMWCWRVTGKJ-UHFFFAOYSA-N 0.000 description 1
- 229960004843 mianserin hydrochloride Drugs 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- KOOAFHGJVIVFMZ-WZPXRXMFSA-M micafungin sodium Chemical compound [Na+].C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS([O-])(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 KOOAFHGJVIVFMZ-WZPXRXMFSA-M 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- SJXULIRYGQTEJK-UHFFFAOYSA-N n'-(2-morpholin-4-ylethyl)methanediimine Chemical compound N=C=NCCN1CCOCC1 SJXULIRYGQTEJK-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960000827 niceritrol Drugs 0.000 description 1
- 229950001071 nicomol Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960003039 nortriptyline hydrochloride Drugs 0.000 description 1
- GPTURHKXTUDRPC-UHFFFAOYSA-N noxiptiline Chemical compound C1CC2=CC=CC=C2C(=NOCCN(C)C)C2=CC=CC=C21 GPTURHKXTUDRPC-UHFFFAOYSA-N 0.000 description 1
- 229950004461 noxiptiline Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- JPAWFIIYTJQOKW-UHFFFAOYSA-N olprinone Chemical compound N1C(=O)C(C#N)=CC(C2=CN3C=CN=C3C=C2)=C1C JPAWFIIYTJQOKW-UHFFFAOYSA-N 0.000 description 1
- 229950005421 olprinone Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
- 229950006124 oxazolam Drugs 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- QMMOXUPEWRXHJS-UHFFFAOYSA-N pent-2-ene Chemical compound CCC=CC QMMOXUPEWRXHJS-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- HYYMPXVEPSKZOU-SPIKMXEPSA-N perphenazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 HYYMPXVEPSKZOU-SPIKMXEPSA-N 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical group C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MVMXJBMAGBRAHD-UHFFFAOYSA-N picoperine Chemical compound C=1C=CC=NC=1CN(C=1C=CC=CC=1)CCN1CCCCC1 MVMXJBMAGBRAHD-UHFFFAOYSA-N 0.000 description 1
- 229950008553 picoperine Drugs 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229940095638 pletal Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 1
- 229960002176 prednisolone sodium succinate Drugs 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical group CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960000918 protionamide Drugs 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960001811 quinine hydrochloride Drugs 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960005456 sisomicin Drugs 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- WFKJEZKHPGDCRK-UHFFFAOYSA-M sodium;2,2,2-trichloroethyl hydrogen phosphate Chemical compound [Na+].OP([O-])(=O)OCC(Cl)(Cl)Cl WFKJEZKHPGDCRK-UHFFFAOYSA-M 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 229940033331 soy sterol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005750 substituted cyclic group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960002573 sultiame Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229950006534 syrosingopine Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 description 1
- 229960003484 testosterone enanthate Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 229960000340 thiopental sodium Drugs 0.000 description 1
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000488 tizanidine Drugs 0.000 description 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229950001089 todralazine Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- 229960005334 tolperisone Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- 229960002301 trazodone hydrochloride Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960002741 triclofos sodium Drugs 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- CHQOEHPMXSHGCL-UHFFFAOYSA-N trimethaphan Chemical compound C12C[S+]3CCCC3C2N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 CHQOEHPMXSHGCL-UHFFFAOYSA-N 0.000 description 1
- 229940035742 trimethaphan Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 150000003703 vitamin D2 derivatives Chemical class 0.000 description 1
- 150000003704 vitamin D3 derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229950004227 zaltoprofen Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a lipid “rich” plaque regression agent useful for prevention or treatment of acute coronary syndrome such as acute myocardial infarction and unstable angina, peripheral arterial occlusion, and the like.
- Drugs that lower blood cholesterol that cause arteriosclerosis include drugs that capture bile acids such as cholestyramine and colestipol and inhibit their absorption (eg, US Patent No. 402). No. 709), drugs such as melinamide that inhibit cholesterol intestinal absorption of cholesterol by inhibiting acetyltransylase (ACAT). No. 69) and other cholesterol synthesis inhibitors, especially oral pasteatin ( Lovastatin ), which inhibits 3-hydroxy-3-methyldartalylchoenzyme A ( HMG_CoA ) reductase. ) (U.S. Pat. No. 4,231,938), Simvastatin (U.S. Pat. No. 4,444,784), Prapastatin
- HMG-CoA reductase inhibitors inhibit not only cholesterol biosynthesis but also components necessary for living organisms such as ubiquinone, dolichol and heme A, there are concerns about side effects caused by them. Is done.
- Acute coronary syndromes (such as unstable angina, acute myocardial infarction and sudden ischemic death) are caused by the formation of a thrombus following the collapse of coronary plaque (atheroma) and the closing of the coronary artery lumen. Occurs.
- Peripheral artery occlusion is caused by the formation of a thrombus following the rupture of arterial plaque (atheroma), thereby occluding the peripheral arterial lumen.
- the nature of the plaque is deeply involved in these diseases, and lipid-rich blurs formed by the accumulation of liposomes such as cholesterol on the inner wall of vascular phages. It is said to cause acute coronary syndrome and peripheral artery occlusion.
- lipid-rich plaque is extremely important for prevention or treatment of acute coronary artery syndromes such as acute myocardial infarction and unstable angina, and peripheral arterial occlusion.
- lipid-rich plaque is also observed in humans whose blood cholesterol level is not high, and the lipid-rich plaque once formed is difficult to remove. It has been desired to provide a drug that efficiently regresses. Since lipid 'litsch plaque is also found in humans whose blood cholesterol level is not high, simply inhibiting ACAT and suppressing intestinal absorption of cholesterol can regress lipid' litsch plaque, Removal would not be sufficient.
- the present invention provides a Lipid'Litsch plaque regression agent useful for prevention or treatment of acute coronary syndrome such as acute myocardial infarction and unstable angina, and peripheral arterial occlusion.
- the present invention provides lipids and lipids exhibiting excellent blood vessel / tissue transportability, directly acting on macrophages containing lipids such as cholesterol, and exhibiting a direct regression effect on atherosclerotic lesions. ⁇ Provides plaque regression agents.
- the present inventors have conducted intensive studies in view of the above circumstances and found that an ACAT inhibitor having a specific structure has unexpectedly excellent lipid-rich 'plaque regression action, Even at a concentration that did not affect the cholesterol level in the medium, they found that they had sufficient lipid-rich-plaque regression action, and completed this honeymoon. That is, the present invention
- Ring A may have a substituent, and may have a cyclic hydrocarbon or a substituent.
- Ring B is a 5- or 6-membered homo- or heterocyclic ring;
- X and Y are each —NR 1 — (R 1 is a hydrogen atom, a carbon atom which may have a substituent;
- R 2a - R 2 and R 2 a are each a hydrogen atom, good hydroxyl group or may have a substituent indicates a hydrocarbon group which may have a substituent
- R 3 is a hydrogen atom, a halogen atom, a hydrocarbon group optionally having a substituent, a hydroxyl group optionally having a substituent, or a hydrocarbon group optionally having a substituent.
- D represents a mercapto group which may be substituted);
- D represents a Ci-g alkylene group optionally substituted with an oxo group or a thioxo group, one NH- or -CH 2 NH one;
- E represents one NR 4 — (R 4 represents a hydrogen atom or a hydrocarbon group which may have a substituent,), one O_, -S (O) n— (n represents 0, 1 or 2) or -CONR 5 - (R 5 is good also have a hydrogen atom or a substituent les, a hydrocarbon group) and
- G is a bond or an alkylene group;
- a r is substituted Moyoi Represents an aryl group or a heterocyclic group which may
- R 4 is B ring constituting atom and together such connection Okiso group or Chiokiso which do or 5- to 7-membered ring optionally substituted with a group
- the ring B may have a substituent in addition to one D-E-G-Ar, and the ring B contains a conjugate or a salt thereof.
- ring A ′ is a 6-membered cyclic hydrocarbon which may have a substituent
- X or Z is one of —NR 1 ′ —
- a ', ring, C, ring and H ring each represent a benzene ring which may have a substituent
- X are one NR 8 — (R 8 is a hydrogen atom or a substituent Represents a hydrocarbon group which may have), one O— or one S—
- U represents — (CH 2 ) m— (m represents 1 or 2) or one NH—
- R a represents a hydrocarbon group, which may have a hydrogen atom or a substituent.
- the A,,, and rings represent a benzene ring which may have a substituent
- the Q ring represents an aromatic ring which may have a substituent
- W represents one CH 2 _, one CO— or _CS—
- V is
- Y ' is one CH.
- the lipid-rich 'plaque regression agent according to the above (1) which has the formula (V)
- R 10 and R 11 are each a hydrogen atom, a hydrogen atom, a halogen atom, a linear hydrocarbon group which may have a substituent or a linear hydrocarbon group which may have a substituent.
- Ring I may be a benzene ring which may have a substituent or a pyridine ring which may have a substituent (preferably a benzene ring which may have a substituent); Represents a benzene ring which may have a substituent or a pyridine ring which may have a substituent.
- the lipid 'rich' plaque regression agent according to the above (1) comprising a compound represented by the formula or a salt thereof:
- R 1C) and R 11 each have a hydrogen atom, a halogen atom or a linear hydrocarbon group which may have a substituent, or have a substituent together with an adjacent carbon atom.
- the lipid-rich plaque regression agent according to (5) which may form a cyclic hydrocarbon,
- R 12 and R 13 each have a hydrogen atom, a halogen atom, or a substituent.
- L ring represents a benzene ring which may have a substituent or a pyridine ring which may have a substituent.
- the lipid / ritsch 'plaque regression agent according to the above (1) which contains the compound represented by the formula or a salt thereof,
- Lipid of the above (1) which is a prophylactic / therapeutic agent for acute myocardial infarction
- R 1 . And R 11 are each a hydrogen atom, a halogen atom, a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted hydrocarbon group.
- a dihydrofuran ring may be formed, and the I ring may be a benzene ring which may have a substituent; a pyridine ring which may have a substituent (preferably a benzene ring which may have a substituent) Ring) represents a benzene ring which may have a substituent or a pyridine ring which may have a substituent.
- R 10 is a hydrogen atom, or a salt thereof
- R 1 1 represents a substituted chain hydrocarbon group
- R 1Q and R 11 each have a hydrogen atom, a halogen atom or a linear hydrocarbon group which may have a substituent, or have a substituent together with an adjacent carbon atom.
- R 12 and R 13 each represent a hydrogen atom, a halogen atom, or a chain hydrocarbon group which may have a substituent, or have a substituent together with an adjacent carbon atom.
- May form a cyclic hydrocarbon Represents a phenyl group which may have a substituent (however, excluding a 2-chlorophenyl group and a monofluorophenyl group), and the L ring represents a benzene ring or a substituent which may have a substituent.
- R 13 is not a methyl group
- R 13 is not a chlorine atom. Or a salt thereof,
- R 12 and R 13 are each a nitrogen atom or The compound according to the above (18), which is an alkyl group,
- cyclic hydrocarbon is C 5 one 7 cyclic hydrocarbon
- the compound according (21) Is a phenyl group which may be substituted with a 3 alkyl group;
- an agent for inhibiting the progression of atherosclerotic lesions comprising a compound having a lipid 'rich' plaque regression action or a salt thereof;
- (31) a method for retreating lipid 'Ritsch plaque in a mammal, which comprises administering an effective amount of the compound or a salt thereof according to the above (1) to the mammal;
- (32) a method for preventing or treating acute coronary syndrome in a mammal, which comprises administering an effective amount of the compound or a salt thereof according to the above (1) to the mammal;
- (33) a method for preventing or treating acute myocardial infarction in a mammal, which comprises administering an effective amount of the compound or a salt thereof according to the above (1) to the mammal;
- a method for preventing or treating unstable angina in a mammal comprising administering to the mammal an effective amount of the compound or a salt thereof according to (1), (35) a method for preventing or treating peripheral arterial occlusion in a mammal, which comprises administering an effective amount of the compound or a salt thereof according to the above (1) to the mammal;
- (36) a method for reducing lipid 'rich blur in a mammal, which comprises administering to the mammal an effective amount of the compound according to (12), a salt thereof or a prodrug thereof;
- a method for reducing lipid 'rich' break in a mammal comprising administering to the mammal an effective amount of the compound according to (18), a salt thereof or a prodrug thereof,
- examples of the cyclic hydrocarbon in the cyclic hydrocarbon optionally having a substituent represented by ring A include C 3 ⁇ .
- Saturated hydrocarbon ring e.g., Shikuropuro pan ring, cyclobutane ring, cyclopentane ring, cyclohexane ring, descriptors down ring, and cyclohexane
- cyclohexene unsaturated hydrocarbon ring examples of C 5 8, cyclopentene ring, cyclohexane Ring, cycloheptene ring, benzene ring, etc.
- c 5 _ 7 Preferred are Japanese hydrocarbon rings (eg, cyclopentane ring, cyclohexane ring, etc.) and C 5 _ 6 unsaturated hydrocarbon rings (eg, cyclopentene ring, cyclohexene ring, benzene ring, etc.), and benzene ring Is particularly preferred.
- substituent in the cyclic hydrocarbon which may have a substituent include (i) a C 1-4 alkyl group which may be halogenated (for example, methyl, chloromethyl, difluoromethyl, trichloromethyl, Trifluoromethyl, ethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, propyl, isopropyl, 3,3,3-trifluoropropyl, butyl, etc.);
- a C alkyl group substituted with a mono- or di-C 4 alkylamino group eg, methylaminomethyl, dimethylaminomethyl, 2-methylaminoethyl, 2-dimethylaminoethyl, etc.
- an alkyl group substituted with a carboxyl group for example, carboxymethyl, carboxyl, etc.
- a 4- alkyl group substituted with a 4- alkoxy group eg, methoxymethyl, methoxethyl, ethoxyxethyl, etc.
- C 3 _ 6 cycloalkyl group e.g., cyclopropyl, cyclobutyl, consequent opening Penchinore, cyclohexylene, etc. Kishinore;
- halogen atoms for example, fluorine, chlorine, bromine, iodine, etc.
- an optionally halogenated alkoxy group for example, methoxy, Fluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, butoxy, isopropyloxy, etc.
- halogenated alkoxy group for example, methoxy, Fluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, butoxy, isopropyloxy, etc.
- — 4 alkoxy group (xiv) optionally halogenated — 4 alkylthio group (eg, methylthio, difluoromethylthio, trifluoromethylthio) , Echiruchio, propylthio, isopropylthio, butylthio, etc.), - 4 alkoxy group or phenoxy optionally substituted d _ 4 even if Arukiruchio group group;
- a cyclic amino group e.g., containing 1 to 3 heteroatoms such as an oxygen atom and a sulfur atom in addition to a nitrogen atom, a 5- to 9-membered cyclic amino group, etc. pyrrolidinyl, Piberiji - Le, piperazinyl, Moruhori - Le etc.); (xviiiO C - 4 alkyl - carbonyl ⁇ amino group (e.g., Asechiruamino, pro Pioniruamino, etc. Puchiriruamino);
- (XX) Mono- or di-C ⁇ 4 alkylamino-carboxy group (for example, methacrylamide / bonyloxy, ethylaminocarbonyloxy, dimethylaminocarbonyloxy, getylaminocarbonyloxy, etc.) ;
- a C ⁇ alkylsulfonylamino group eg, methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, etc.
- (XXV) a C ⁇ e alkyl monoluponyl group (eg, methylcarbonyl, ethylcarboninole, butinolecanoleponinole, etc.);
- (XXX) 1_ _ 4 alkyl eg, methyl
- 2 — 4 alkylsulfonyl eg, methylsulfonyl
- 3 C- 4 alkyl which may be halogenated (eg, methyl, trifluoromethyl) , halogen (e.g., fluorine, chlorine) or a hydroxy Le group which may have a c 6 - 1 2 Ariru group (e.g., phenyl, naphthyl, human Dorokishifue two Honoré, Mechinorefue two Honoré, black hole Hue such as a secondary Honoré) , 4 C 7 - i 5 ⁇ aralkyl (e.g., benzyl, etc.), 5 _ 4 alkoxy eleven 4 alkyl
- a 5- to 9-membered heterocyclic group containing 1 to 3 heteroatoms such as nitrogen, oxygen, and sulfur atoms in addition to carbon atoms e.g., piperidinyl, piperanidyl , Morpholinyl, chenyl, furyl, pyridyl, pyrimidininole, thiazolinole, benzothiazolinole, benzisothiazolyl, benzoxoxazoly ⁇ ⁇ , benzoisoxazolyl, etc.
- a cyclic amino group substituted with one or two substituents selected from e.g., a 5- to 9-membered cyclic group which may contain 1 to 3 hetero atoms such as an oxygen atom and a sulfur atom in addition to a nitrogen atom
- Amino groups and the like specifically, for example, pyrrolidinyl, piperidinyl, piperaziel, 3,6-dihydropyridine-11 (2 ⁇ ) — Le, [1, 3] thiazolo [4, 5-b] pyridine one 3 (2 H) - I le, Moruho Riniru etc.) substituted
- Flip E _ 6 alkyl group e.g., morpholinomethyl, 4 one Fueenore 1 1-piperogenolemethinole, 2-morpholinoethyl, 3-pirazuryl propyl, 4-methylsulfonyl-piperazinyl-methyl, 4-benzyl-111-piperazinyl-methyl, 4- (4-hydroxypheny
- (xxxi) a 4- alkyl group substituted by an alkyl-carbonyloxy group (for example, methylcarbonyloxy, ethylcarboxy-, butylcarbonyloxy, etc.);
- (XXXV) a C 4 alkyl group substituted with a C 6 alkyl monocarbonyloxy group (eg, methylcarbonyloxy, ethylcarbonyloxy, butylcarbonyloxy, etc.);
- C 3 _ 6 cycloalkyl group e.g., cyclopropyl, etc.
- halogenated may ⁇ DOO 4 alkoxy group (e.g., main butoxy, Jifuruorome butoxy, Torifuruorome butoxy, ethoxy, etc.), Ji may be (vi) halogenated ⁇ - 4 Arukiruchio group ( For example, methylthio, trifluoromethylthio, ethylthio, etc.), (vii) amino group, (viii) mono- or di-. D alkylamino group
- a cyclic amino group which may be substituted for example, a 5- to 9-membered cyclic amino group which may contain 1 to 3 hetero atoms such as an oxygen atom and a sulfur atom in addition to a nitrogen atom
- such group specifically, for example pyrrolidinyl, piperidinyl, C ⁇ substituted by morpholinyl, etc.
- - 6 alkyl group e.g., morpholinomethyl, 4-phenyl one 1-piperazinylmethyl, 2 one Moruhorinoechiru, 3 (Piperazinylpropyl etc.) and (xi) hepoxyl group, etc., particularly, (i) halogen atom (for example, If, Furuoro, etc.
- J j alkoxy group for example, methoxy, Ethoxy, etc.
- C 6 - 1 2 Ariru group e.g., phenyl, naphthyl, etc.
- optionally substituted cyclic amino group e.g., an oxygen atom in addition to the nitrogen atom, a hetero atom such as sulfur
- a 5- to 9-membered cyclic amino group which may contain 1 to 3 such as, for example, pyrrolidinyl, piperidinyl, piperazinyl, 3,6-dihydropyridine-1 (2H) fr, morpholinyl C substituted, etc.), - 6 Anorekiru group (e.g., morpholinomethyl, 4 one phenylene Lu 1-piperazinyl-methyl, 2-morpholinoethyl, (4 one phenylene Lou 3, 6-dihydropyridine one 1 (2 H) -Ylmethyl), 3-piperazinylpropyl, etc.) and (vii) a carb
- the heterocyclic ring in the optionally substituted heterocyclic ring represented by ring A may be, for example, a heteroatom such as nitrogen, oxygen, sulfur atom and the like in addition to a carbon atom.
- aromatic heterocycle examples include a furan ring, a thiophene ring, a pyrrole ring, an oxazoline ring, an isosoxazoline, a thiazoline ring, an isothiazoline ring, an imidazole ring, a pyrazole ring, a 1,2,3-oxadiazole ring, 1 1,2,4-oxadiazole ring, 1,3,4-oxadiazole ring, 1,2,5-oxadiazole ring, 1,2,3-thiadiazole ring, 1,2,4-thiadiazole ring, 1,3,4 —Aromatic monocyclic heterocycles such as thiaziazole ring, 1,2,3-triazole ring, 1,2,4-triazole ring, tetrazo mononole ring, pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring and triazine ring
- a pyridine ring, a pyridazine ring, a thiazonole ring, a thiadiazoline ring, and the like, and a furan ring, a thiophene ring, and a pyridine ring are particularly preferable.
- Examples of the above-mentioned substituents which the heterocyclic group which may have a substituent may include (i) an alkyl group which may be halogenated (for example, methyl, chloromethinole, dif Noreolomethinolle, trichloromethinolle, trifinolemethinole, Chill, 2, 2-Jipuromoechiru, 2, 2, 2 _ triflumizole Ruo Roe chill, propyl, I an isopropyl, 3, 3, 3-triflate Ruo b propyl, butyl, etc.); (ii) C 3 _ 6 consequent opening alkyl group (E.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.); (iii) halogen atom (e.g., fluorine, chlorine, bromine, iodine, etc.); (iv) nitro group; (V) cyan
- JC ⁇ alkylsulfonylamino group for example, methinolesnolezonizoleamino, etylsulfoamino, rubynonyloxy, ethylaminopropyl, dimethylaminocarboxy-, dimethylaminocarbonyloxy, etc.
- a C 4 alkoxy mono-norborneol group for example, methoxycarbonyl, ethoxycarbol, propoxycarbol, isobutoxycarbonyl, etc.
- C ⁇ 6 alkyl Le one carbonyl group e.g., Mechirukarubo - Le, E chill carbonyl, etc.
- substituents such as 1-oxoethyl, 1-oxopropyl, 1-oxobutyl and the like.
- Etc. are used. These substituents may be substituted at the substitutable position with the same or different one to five, preferably one to three. Preferred as these substituents are (i) a halogen atom (for example, fluorine, chlorine, bromine and the like), and (ii) a halogenated atom.
- alkyl group e.g., methyl, chloromethyl, Jifuruoromechiru, triflumizole Honoré Oro methyl, E chill, propyl, isopropyl, etc.
- C 3 one 6 cycloalkyl group e.g., cyclopropyl, etc. consequent opening heptyl
- Iv a hydroxyl group
- V an alkoxy group which may be halogenated (for example, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, etc.), and (vi) a halogenated group.
- alkylthio groups e.g., methylthio, trifluoromethylthio, ethylethyl (Vii) an amino group, (viii) a mono- or dialkylamino group (for example, methinoleamino, ethinoleamino, dimethinoleamino, getylamino, etc.), (ix) an alkoxycarbyl group (for example, methoxycarbol, Examples include (i) a halogen atom (eg, fluoro, chloro, etc.), (iiO C i alkyl (eg, methyl, ethyl, etc.), ( iii) C 3 _ cycloalkyl groups (eg, cyclopropyl, cyclobutyl, etc.), (iv) hydroxyl groups, WC alkoxy groups (eg, methoxy, ethoxy, etc.) and (vi) carboxyl groups.
- the 5-membered or 6-membered homocyclic ring represented by ring B is, for example, a cyclopentane ring or a cyclohexene ring. Ring, cyclopentene ring, cyclohexene ring, cyclopentadiene ring, cyclohexadiene ring, benzene ring, etc.
- the 5- or 6-membered heterocyclic ring represented by ring B is, for example, a cyclopentane ring Or a 5- or 6-membered heterocyclic ring containing 1 to 3 heteroatoms such as nitrogen, oxygen, sulfur, etc. in place of 1 to 3 carbon atoms in the ring of hexane.
- the substituent may be, for example, a cyclic hydrocarbon which may have a substituent described above in addition to an oxo group, a thioxo group or the like. Is a group derived from a heterocyclic ring which may have a substituent. Of these, (i) a group which is conducted by a cyclic hydrocarbon having a substituent, (ii) an oxo group, and (iii) a thioxo group are preferable, and a phenyl group and an oxo group which may have a substituent. And thioxo groups are particularly preferred.
- the substituents that the fuel group may have have the same meaning as the substituents in the cyclic hydrocarbon, which may have the above substituents.
- examples of the hydrocarbon group in the hydrocarbon group which may have a substituent represented by RR 2 , R 2 R 3 , R 4 and R 5 include, for example, an aliphatic chain type
- a hydrocarbon group, an alicyclic hydrocarbon group and an aryl group are exemplified, and among them, an aliphatic chain hydrocarbon group is preferable.
- Examples of the aliphatic chain hydrocarbon group of the hydrocarbon group include a linear or branched aliphatic hydrocarbon group, for example, an alkyl group, an alkenyl group, and an alkynyl group. Among them, a linear or branched alkyl group is preferred.
- Examples of the alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentinole, neopentinole, 1-methylpropyl, n-hexyl, and iso-isobutyl.
- hexyl, 1, -1-dimethylbutyl, 2, 2-dimethylol Norev Chino les, 3, 3-dimethyl butyl Honoré, 3, 3-dimethyl propylene Honoré, 2 Echirubuchiru include C i_ 7 alkyl such as heptyl to n-, Above all, n One propyl, isopropyl, isobutyl, C 3 _ 5 alkyl are preferred, such as neopentyl, especially isobutyl, neopentyl, etc. are Shi favored.
- alkenyl group examples include butyl, aryl, isopropyl, 2-methylaryl, 1-propylenol, 2-methynol — 1-propyninole, 2-methynolene 2-propynenol, 1-loop, Tenonore, 2-Pteninole, 3-buteninole, 2-ethinole _1-buteninole, 2-methinole 2-butur, 3-methyl-2-butur, 1-pentul, 2-pentenyl, 3-penteninole, 4 _ Penten 2 7, 4- Mechinore 3-Penten 2, 1-Hex 2, 2-Hex-Zole, 3-Hex 2 / Le 4-Hexeninole 5-Hexeninole 2 _ 6 alkenyl.
- alkynyl group examples include ethyl, 1-propyl, 2-propyl, 1-butyninole, 2-butul, 3-butyninole, 1-pentinole, 2-pentinole, 3-pentinole, 4 one pliers two Honoré, Kishininore to 1, carboxymethyl two / Les to 2, Kisheru to 3, 4 to Kishininore, are C 2 _ 6 alkynyl, such as key Shin Il cited to 5, among others Echuru, 1 one Purobyuru , 2-propynole and the like are particularly preferred.
- Examples of the alicyclic hydrocarbon group of the hydrocarbon group include a saturated or unsaturated alicyclic hydrocarbon group, for example, a cycloalkyl group, a cycloalkenyl group, a cycloalkadienyl group and the like.
- the cycloalkyl group is preferably a cycloalkyl group having 3 to 9 carbon atoms, and examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and the like. , Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
- C 3 -cycloalkyl groups are preferred.
- the cycloalkenyl group include 2-cyclopentene-1-ynole, 3-cyclopentene-1-ynole, 2-cyclohexene-1-ynole, 3-cyclohexene-1-ynole, 1-cyclobutene-11-yl, 1 Shiku port pentene one 1 Iru C such as 5 - 6 Shikuroaruke - Le group.
- Examples of the cycloalkadienyl group include 2,4-cyclopentadiene 1-isle, 2,4-cyclohexadiene 1-inole, and 2,5-cyclohexadiene - 1 one I Le of C 5 - 6 cycloalkanols diethyl - such as Le group.
- aryl group of the hydrocarbon group examples include monocyclic or condensed polycyclic aromatic hydrocarbon groups having 6 to 16 carbon atoms, such as phenyl, naphthyl, anthryl, phenanthryl, and acenaphthylenyl. Ce-i such as phenyl, 1-naphthyl and 2-naphthyl. Are particularly preferred.
- substituents include an optionally substituted aryl group, an optionally substituted cycloalkyl group or a cycloalkenyl group, and an optionally substituted heterocyclic group.
- a halogen atom eg, fluorine, chlorine, bromine, iodine
- the Ariru group optionally Ariru group which may be the substituent, Fueeru, naphthyl Le, anthryl, Fuenantoriru, C 6 such Asenafuchireniru - include 1 6 Ariru group, inter alia phenyl, 1 one-naphthyl, 2-naphthyl, etc. C e ⁇ .
- the aryl groups are preferred. Examples of the substituent of the aryl group include (i) an alkoxy group which may be halogenated (eg, methoxy, ethoxy, propoxy, trifluoromeloxy, etc.), (ii) a halogen atom (eg, fluorine, chlorine, bromine, Iodine) ,
- an optionally halogenated 6 alkyl group eg, methyl, ethyl, propyl, trifluoromethyl, etc.
- an optionally halogenated 6 alkyl group eg, methyl, ethyl, propyl, trifluoromethyl, etc.
- Examples of the cycloalkyl group cycloalkyl group which may optionally be said substituted consequent opening Puropinore, Shikuropuchinore, consequent opening Penchinore, Kishinore cyclohexane, C 3 of heptyl and the like cyclohexane - like 7 cycloalkyl group.
- Examples of the substituent of the cycloalkyl group and the number of the substituent include the same kind and number as the substituent of the optionally substituted aryl group.
- cycloalkenyl group of the optionally substituted cycloalkenyl group Shikuropuro Bae Ninore, Shikurobuteninore, cyclopent two Honoré, etc. C 3 _ 6 cycloalkenyl group Kiseninore like cyclohexane and the like.
- substituent of the cycloalkenyl group and the number of the substituent include the same kind and number as the substituent of the optionally substituted aryl group.
- the substituted or heterocyclic group of the heterocyclic group includes at least one, preferably 1 to 4 hetero atoms of oxygen, sulfur and nitrogen as atoms constituting the ring system (ring atoms).
- Examples thereof include an aromatic heterocyclic group having an atom and a saturated or unsaturated non-aromatic heterocyclic group (aliphatic heterocyclic group), and an aromatic heterocyclic group is preferable.
- the aromatic heterocyclic group include a 5- to 6-membered aromatic monocyclic heterocyclic group (eg, furyl, phenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, virazolyl, 1,2,3- 1,2,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, frazur, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3 —Triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazy
- non-aromatic heterocyclic group examples include 4- to 9-membered non-aromatics such as oxilanyl, azetidinyl, oxetanyl, cetanyl ⁇ pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperidyl, tetrahydrovinylanyl, morpholinyl, thiomorpholinyl, piperazyl and the like.
- Heterocyclic groups (especially one to three heteroatoms such as oxygen and sulfur atoms in addition to nitrogen atoms such as pyrrolidinyl, piperidiel, piperazinyl, morpholinyl, 3,6-dihydropyridyl-1 (2 ⁇ ) -yl) which may be a 5- to 9-membered cyclic amino group).
- Heterocyclic group may have 1 to 4 preferably 1-2 substituents, examples of such substituents, ⁇ preparative 6 alkyl group (e.g. methyl, Echiru, propyl, .eta. Butyl, ⁇ -hexyl, etc.),.
- Ariru group e.g., phenyl
- hydro Kishi C 6 - 1 2 Ariru group e.g., 4-hydroxyphenyl
- 4 Arukirusu Ruhoniru group e.g., methylsulfonyl
- Ararukiru group e.g., benzyl
- C i _ 4 alkoxy one alkyl group e.g., Puropokishechiru
- nitrogen atom in addition to carbon atoms oxygen 5 to 9-membered heterocyclic group containing 1 to 3 heteroatoms such as atoms and sulfur atoms (for example, piberidyl, piperanidyl, morpholiel, chenyl, furyl, pyridyl, pyrimidinyl, thiazolyl, benzothiazolyl, benzoy And a hydroxyl group, an oxo group, a thioxo group, and the like.
- substituent in the optionally substituted amino group include, for example, lower (C ⁇ alkyl (eg, methyl, ethyl, propyl, etc.), carbon atom 5 to 9-membered heterocyclic group containing 1 to 3 hetero atoms such as nitrogen, oxygen, sulfur, etc. (eg, chenyl, furinole, pyridyl, pyrimidininole, thiazoli ⁇ ⁇ , benzothiazolinole, .
- Benzoisochia Zoriru benzo O hexa benzisoxazolyl, benzoisoxazolyl O hexa benzisoxazolyl etc.
- alkyl one carbonyl group e.g., methylcarbonyl, E chill carbonyl, etc.
- C 6 - 1 2 Ari Lou carbonyl group e.g., Benzoiru etc.
- C i _ 4 alkyl-sulfonyl group 4 alkoxy one C ⁇ _ 4 alkyl group, and the like.
- the substituent further includes a C i-e alkyl group (eg, Methyl, ethyl, propyl, n-butyl, n-hexyl, etc.)
- the optionally substituted hydroxyl group examples include a hydroxyl group, an optionally halogenated 16 alkoxy group, preferably an optionally halogenated alkoxy group, and more preferably an alkoxy group (eg, methoxy, ethoxy) , Propoxy, butoxy, t-proxy, etc.), 6- alkyl-l-oxyloxy group (eg, methylcarbonyloxy, ethynolecarbonyloxy, petylcar- propyloxy, etc.), aminocarboxy-loxy group, monono or di
- Etc. _ 4 alkyl ⁇ iminocarbonyl O alkoxy group.
- Ji may be halogenated sheet 1 6 alkylthio group, preferably C 4 alkylthio group which may be halogenated, more preferably C i- 4- to 5-membered heterocycles containing 1 to 3 hetero atoms such as 4 alkylthio groups (eg, methylthio, ethylthio, etc.), nitrogen, oxygen, sulfur, etc.
- 4 alkylthio groups eg, methylthio, ethylthio, etc.
- acyl group a formyl group, a 6 alkyl monocarbonyl group, preferably
- C _ 4 alkyl monocarbonyl group eg, methylcarbonyl, ethylcarbonyl
- ⁇ alkoxy monocarbonyl group eg, methoxycanoleponyl
- C ⁇ 6 alkyl monosulfol group preferably C i _ 4 alkyl one sulfonyl group (e.g., Mechirusuruhoni Honoré, Echirusuruhoniru)
- C r _ 4 alkoxycarbonyl Kishi sulfonyl group e.g., main Tokishisuru Honiru
- Examples include a rubamoyl group, a mono- or dialkyl 4- alkylcarbamoyl group, and the like.
- the substituent of the hydrocarbon group is a halogen atom; an amino group; ( 4) alkylamino group; alkoxyl group; alkoxy Carbonyl group; hydroxyl group; may be halogenated. -4 alkoxy group; c 3 _ 6 cycloalkyl group; a nitro group; Shiano group; but it may also be halogenated - 4 alkylthio group; a cyclic amino group (e.g., an oxygen atom in addition to the nitrogen atom, such as sulfur atoms A C 5 alkyl monocarbonyl containing 1 to 3 heteroatoms, which may be a 5 to 9-membered cyclic amino group, such as pyrrolidinyl, piperidinyl, piperazur, and morpholinyl; amino group; Aminokarubo - Ruo dimethylvinylsiloxy groups; mono- or di - 4 alkylaminocarbonyl O dimethylvinylsiloxy groups; 4
- C E _ 4 alkyl and - Amino group substituted by a carbonyl C 1 -4 alkyl and C 6 ⁇ 2 Amino group substituted by Ariru Ichiriki Ruponiru; alkyl - Cal Boniruokishi group; a mono- or di-C l - 4 alkoxy one 4 Arukiruamino group; a nitrogen atom in addition to carbon atom, an oxygen atom, A 5- to 9-membered heterocyclic monothio group containing 1 to 3 hetero atoms such as a sulfur atom; and 1 to 4 substituents selected from oxo groups and the like are used.
- hydroxyl group e.g., (i) hydroxyl groups, (i C ⁇ A an alkoxy group (e.g., main butoxy, ethoxy, propoxy, Isopurobokishi, butoxy, t Putokishi), (iii) C 6 - 1 0 Ariruokishi group (e.g., Fueniruokishi, etc.
- C ⁇ 4 alkyl Ichiriki Ruponiruokishi group e.g., e Noremiruokishi, Asetokishi, propionate -, etc. Ruokishi
- C 2 - 6 Arukanoi Ruokishi group e.g., Asechiruokishi, propionyl Okishi, Bareriruokishi, etc.
- the optionally substituted amino group represented by R 1 includes, for example, (1) a 0 ⁇ 4 alkyl group (eg, methyl, ethyl, propyl, isopropyl, etc.), (ii) alkyl one carbonyl group (e.g., Asechiru, propionitrile two Le, butyryl, etc.), (ii C ⁇ 4 alkoxy - Karuboeru groups (e.g., main Toki Shikaruponiru, ethoxycarbonyl, propoxycarbonyl), (i v) halogen Atoms (eg, fluorine, chlorine, etc.), (V) phenyl, (viO C ⁇ 4 alkyl-phenyl (eg, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, etc.), (vii) halogenated phenyl (e.g., 4-black port phenyl, three to black port Hue - le, 2- Clos
- examples of the mercapto group which may be substituted with a hydrocarbon group which may have a substituent represented by R 3 include, for example, the above-mentioned hydrocarbon group which may have a substituent And a mercapto group which may be substituted with a hydrocarbon group which may have the same substituent as described above.
- an alkylthio group for example, methylthio, ethylthio, propylthio, etc.
- the alkylene group in the 3 alkylene group which may be substituted with the oxo group or thioxo group represented by D is, for example, one CH
- alkylene group substituted with the oxo group or the oxo group examples include one CO_, one CS-, _CH 2 CO-, _CH 2 CS-, _CH 2 CH 2 CO-, and one CH 2 CH 2 CS-. No.
- D is preferably (i) C ⁇ optionally substituted with an oxo group.
- the 5- or 7-membered ring contains, for example, 1 to 3 nitrogen atoms which may be substituted with an oxo or thioxo group together with a constituent atom of the B ring adjacent to a constituent atom of the B ring to which D is bonded.
- 7-membered to 7-membered saturated heterocycles and particularly preferred are 5- or 6-membered saturated heterocycles containing one nitrogen atom! / ,.
- M a ring may be substituted by Okiso group or Chiokiso group; h is 3 Power 2 et 5 integer; and the other symbols are as defined above.
- the M a 'ring may be substituted with an oxo group; other symbols are as defined above.
- preferred examples of E include, for example, one NR 4 ′ — (R 4 ′ is a hydrogen atom or optionally substituted methyl, ethyl, n-propyl, n-butyl, isopropyl Represents a C 6 alkyl group such as, hexyl, etc.), -CONR 5 '-(R 5 ' is a hydrogen atom or an optionally substituted methyl, ethyl, n-propyl, n-butyl, isopropyl, And a Ce alkyl group such as hexyl.
- R 4 ′ and R 5 ′ may have have the same meaning as the substituents that the above-mentioned hydrocarbon group which may have may have.
- E is one CONR 5 '- (R 5' which may have a water 3 ⁇ 4 atom or a substituent methyl, Echiru, n- propyl, n- butyl, C i-6 alkyl of cyclohexyl and isopropyl, the Is particularly preferred.
- the membered ring contains, for example, 2 to 4 nitrogen atoms which may be substituted with an oxo group or a thioxo group together with the constituent atoms of the B ring adjacent to the constituent atoms of the B ring to which R 4 is bonded.
- 5 Preferred are a 7-membered to 7-membered saturated heterocycle, and a 5- or 6-membered saturated heterocycle containing two nitrogen atoms is particularly preferred.
- M b ring may be substituted by Okiso group or Chiokiso group; i is an integer of 1 a stone 3; and ⁇ , the total number of carbon atoms constituting atoms and one (CH 2) i- of D Is 2 to 4; other symbols are as defined above. ],
- i is an integer of 1 a stone 3; and ⁇ , the total number of carbon atoms constituting atoms and one (CH 2) i- of D Is 2 to 4; other symbols are as defined above.
- D is one CO—
- E is NR 4 — (R 4 is as defined above)
- G is one CH 2 — or one CH 2 CH 2 —
- D is one CO—
- E is —NR 4 — (R 4 is as defined above)
- G is a bond
- D is _CH 2 CO— or _CH 2 CH 2 CO_
- E is —NR 4 — (R 4 is as defined above)
- G is a bond
- D is _CH 2 CO— or one CH 2 CH 2 CO—
- E is —NR 4 — (R 4 Is as defined above)
- G is —CH 2 — or one CH 2 CH 2 —
- D is —CH 2 — or one CH 2 CH 2 —
- E is 10—
- G is _CH 2 — Or one CH 2 CH 2 —
- D is one CH 2 — or one CH 2 CH 2 —
- E is — NR 4 —
- Ar represents an aryl group which may have a substituent or a heterocyclic group which may have a substituent.
- the aryl group in the aryl group which may have a substituent represented by Ar is, for example, Ce ⁇ such as phenyl and naphthyl. Preferred are aryl groups and the like, and particularly preferred are, for example, phenyl groups.
- the aryl group represented by Ar may have 1 to 5 identical or different substituents, and preferably 1 to 3 substituents. They may be substituted at any position on the ring.
- Examples of the strong substituent include (i) an optionally halogenated C ⁇ 4 alkyl group (for example, methyl, chloromethyl, difluoromethyl, trichloromethinole, trif / leo-methinole, ethinole, 2-bromoene) chill, 2, 2, 2-triflate Ruo Roe chill, propyl, Isopuropiru, 3, 3, 3-preparative Riffle O b propyl, heptyl), (ii) amino C 4 alkyl group substituted with a group (e.g., amino methyl, such as 2 _ aminoethyl), (iii) mono one or di- c, _ 4 Arukiruamino substituted ci _ 4 alkyl group with a group (e.g., Mechiruamino methyl, dimethicone Honoré aminomethyl, 2-methylaminoethyl, 2- (Iv) C4 alkyl group substituted with carboxyl
- Alkoxy groups for example, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trif / leo ethoxy, propoxy, butoxy, isopropoxy
- halogenated 4 alkylthio groups e.g., methylthio, difluoromethylthio, trifluoromethylthio, Chiruchio, propylthio, isopropylthio, etc.
- C ⁇ 4 alkyl group for example, methyl, chloromethyl, di
- ⁇ 4 alkoxy groups for example, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propyloxy, butyloxy, isopropyloxy, etc.
- halogenated good alkylthio O group e.g., methylthio, difluoromethyl O b methyl thio, triflumizole Ruo b methylthio, Echiruchio, propylthio, isopropylthio, butylthio, etc.
- amino group e.g., mono- one or di- one C ⁇ 4 alkylamino Groups (eg, methylamino, ethylamino, propylamino, dimethylamino, acetylamino, etc.)
- Ci-alkoxy monopropanol groups eg, methoxycarbonyl, ethoxycarbonyl, propoxy
- substituents include (i) an optionally halogenated C i- 4 alkyl group (for example, methyl, chloromethyl, difluoromethyl, trichloromethinole, trifrenoleolomethinole, ethinole, 2-bromoethynole) , 2,2,2-trifluoroethyl, propyl, isopropyl, 3,3,3-trifluoropropyl, etc.), (ii) halogen atom (for example, fluorine, chlorine, bromine, etc.), (iii) nitro group, (iv) a hydroxyl group, (V) an optionally halogenated C 1-4 alkoxy group (for example, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, etc.), (Vi) amino group, (vii) mono or di C 1 - 4 Arukiruamino substituted
- i 4 alkyl group with a group e.g., Mechiruaminome chill, dimethylcarbamoyl Honoré aminomethyl, 2-methylaminoethyl, 2-dimethylaminoethyl an ethyl, etc.
- mono- or di-one C ⁇ 4 alkylamino group e.g., methyl amino, Echinoreamino, Jimechinoreamino, etc. Jechinoreamino
- ii C i 4 ⁇ Norekokishi one carbonyl group e.g., main butoxycarbonyl, etc.
- a carboxyl group Contact Yopi ( xi) carbamoyl group and the like, and particularly preferably an alkyl group which may be halogenated (for example, methyl, methyl methinole, diphnoleolomethyl, trichloromethinole, trifluoromethyl, ethynole, 2- Bromoethyl, propyl, isopropyl, etc.), halogen atom (for example, they may be fluorine, chlorine, bromine and the like, and may be nitrogenated — 4 alkoxy groups (for example, methoxy, trifluoromethoxy, ethoxy, propoxy, etc.)
- Ar Examples of the heterocyclic group in the optionally substituted heterocyclic group represented by are, for example, 1 to 4 hetero atoms such as nitrogen, oxygen, and sulfur atoms in addition to carbon atoms, preferably A 5- or 9-membered,
- aromatic heterocyclic group examples include, for example, furyl, phenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,3, 4-oxadiazolyl, furazael, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, Aromatic monocyclic heterocyclic groups such as pyridyl, pyridazyl, pyrimidinyl, virazinyl, and triazinyl, or, for example, benzofuranyl, isobenzofuranyl, benzo [b] chenyl, indolyl, isoindolyl, 1
- H-indazolinole benzoimidazolinole, benzoxazolyl, 1,2-benzoisoxazolinole, benzothiazolyl, 1,2-benzoisothiazolyl, 1H-benzotriazolyl, Quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinini / le, phthaladur, naphthyridinyl, prill, pteridinyl, force Rubazolyl, a-Carporinyl,] 3-Carporinyl, ⁇ -carbolinyl, acridinil, phenoxazinyl, phenothiazinyl, fenadinyl, fenoxatii / re, thiantreninole, fenatorininole, fenatoroliniire, lindriginig, 2-b] pyridazinole, pyrazo mouth
- a 5- or 6-membered heterocyclic group is preferable, and examples thereof include, for example, furyl, phenyl, pyrrolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, quinolyl, isoquinolyl, thiazolyl, and thiadiazolyl. -Le and the like are used. Particularly, for example, frill, chenyl, pyridyl and the like are preferable.
- Examples of the substituent which the heterocyclic group which may have a substituent represented by Ar may have include, for example, (i) a trialkyl group which may be halogenated (for example, methynole, Chloromethinole, diphnoleolomethinole, trichloromethinole, trifinolelomethinole, etinole, 2,2-dipromoetinole, 2,2,2_triphnoleolotineole, propyl, isopropyl, 3,3,3-trifluorofluoropropyl , butyl, etc.), (ii) C 3 - 6 cycloalkyl group (e.g., cyclopropyl, Shikuropuchiru, cycloalkyl pentyl, cyclo hexyl, etc.), (ii i) a halogen atom (e.g., fluorine, chlorine, bromine, ®
- Harogenihi which may also be 4 Arukiruchio group (e.g., methylcarbamoyl Lucio, Ziv Honoré Oro methyl thio, triflumizole Ruo b methylthio, Echiruchio, propyl thio, isopropylthio, etc.
- Harogenihi which may also be 4 Arukiruchio group (e.g., methylcarbamoyl Lucio, Ziv Honoré Oro methyl thio, triflumizole Ruo b methylthio, Echiruchio, propyl thio, isopropylthio, etc.
- Kishirusuruhoniru such as methyl, Echiru, propyl, butyl , alkyl groups such as isopropyl, methoxy, ethoxy, n- propyl Ruokishi, i- Puropiruokishi, n - C Bok 4 alkoxy group such Buchiruokishi, for example black hole, bromo, halogen atom such as Yodo, hydroxyl groups, benzyl Okishi group , amino group, mono- or di ⁇ preparative 4 alkylamino group, nitro groups, C ⁇ - 6 alkylcarbonyl group 1 selected from such three substituents which may be substituted, each of phenyl or naphthyl Good phenyl, naphthyl, phenoxy, benzoyl Phenoxyethanol carbonyl, Hue - Lou alkyl force Luba moil, Hue - Rukanorebamoiru, Hue - Lou Aruk
- a halogen atom e.g., full Tsu-containing, chlorine, bromine, etc.
- optionally halogenated good C i _ 4 alkyl group e.g., methyl, Kuroromechinore , Jifuruoromechiru, triflumizole Ruo Russia methyl, E chill, propyl, isopropyl, etc.
- C 3 - 6 cycloalkyl group e.g., consequent opening propyl, consequent opening heptyl
- i v) hydroxyl group (V) It may be lip gent.
- alkoxy group eg, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, etc.
- a halogenated C- 4 alkylthio group eg, methylthio, trifluoromethylthio, ethylthio, etc.
- an amino group e.g. mono or di.
- 4 Alkylamino groups for example, methylamino, ethylamino, dimethinoleamino, acetylamino, etc.
- JC ⁇ 4 alkoxy-carboxy groups for example, methoxycarbonyl, ethoxycarbonyl, etc.
- X carboxyl group, etc.
- halo gen atom e.g., Furuoro, etc. black port
- C j _ 4 alkyl e.g., methyl, etc. Echiru
- C 3 _ 6 cycloalkyl group e.g., cyclopropyl, etc. Shikuropuchi Le
- human Dorokishiru group ⁇ - 4 alkoxy group (e.g., main butoxy, ethoxy, etc.) and carboxyl group are preferred.
- halogenated may ⁇ DOO 4 alkyl group (e.g., methyl, Jifuruoromechiru, preparative Rifuruoromechiru, Echiru, 2, 2, 2-triflate Ruo Roe Chill , Propyl, isopropyl pill, etc.) and optionally nodulated alkoxy groups (for example, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoromethoxy, propoxy, isopropoxy, etc.) And a phenyl group optionally having 1 to 3 substituents selected from the group consisting of:
- one halogenated C 1-4 alkyl group eg, methyl, trinoleolomethy
- Le Echiru etc.
- C ⁇ 4 alkoxy group e.g., main butoxy, ethoxy, Provo alkoxy
- 5- or 6-membered heterocyclic groups containing one to three heteroatoms eg nitrogen, oxygen, sulfur, etc.
- one to three heteroatoms eg, furyl, pyridyl, pyrimidyl, Chenyl, thiazolyl, thiaziazolyl, etc.
- carbon atoms eg, furyl, pyridyl, pyrimidyl, Chenyl, thiazolyl, thiaziazolyl, etc.
- halogen atom e.g. chlorine, fluorine, etc.
- halogenated ⁇ may DOO 4 alkyl group (e.g. methyl, triflumizole Ruoromechiru, Echiru, isopropyl), optionally halogenated good Ji ⁇ _ 4 alkoxy group (e.g. methoxy, Torifuruorome butoxy, ethoxy, etc.), (such as Jimechiruamino) di one 4 alkylamino group, 3 Ashiruoki sheet groups (such as Asetokishi) and 4 to 1 selected from hydroxyl groups A phenyl group or a pyridyl group which may be substituted with a substituent is used.
- Preferred examples of the compound represented by the formula (I) or a salt thereof include a compound represented by the formula (II)
- the ring A ′ represents a 6-membered cyclic hydrocarbon which may have a substituent
- the ring C represents a benzene ring which may have a substituent
- R 1 ′ represents a hydrogen atom, a hydrocarbon group which may have a substituent or an amino group which may have a substituent), one O— or one S—, and the other one —CO— , -c S- or a C (R 2 ') R 2a ' - (R 2 ' and R 2 a' represent, respectively, a hydrogen atom or an optionally substituted hydrocarbon group) and or any,
- An optionally substituted hydrocarbon group, an optionally substituted amino group, an optionally substituted hydroxyl group or an optionally substituted Yin represents a single bond or a double bond;
- Y ′ represents one CR 6 — (R 6 represents a hydrogen atom,
- D' is an oxo group or a thioxo group
- E ′ represents —NR 7 — (R 7 represents a hydrogen atom or a hydrocarbon group which may have a substituent), and one O— or one S (O) n — (N represents 0, 1 or 2);
- G ′ represents a bond or a C 3 alkylene group; and
- Ar ′ represents an aryl group or a substituent which may have a substituent.
- D ′ may be taken together with Z ′ to form a 5- or 7-membered ring which may be substituted with an oxo or thioxo group, and R 7 is Together they may form a 5- or 7-membered ring which may be substituted by an oxo or thioxo group. Or a salt thereof.
- substituents that the A ′ ring and the C ring may have include a cyclic hydrocarbon that may have a substituent represented by the ring A in the formula (I). It has the same meaning as the substituent that may be present.
- D 'and Z may be combined to form a "5- or 7-membered ring optionally substituted by an oxo group or a thioxo group", in which the constituent atoms of the D and B rings are united. 5 to 7 members which may be substituted by an oxo group or a thioxo group Member ring ".
- R 7 and Z are together a connexion formed "5-membered to 7-membered ring optionally substituted with Okiso group or Chiokiso group" which may be the a together the constituent atoms of the R 4 and B ring connexion It may have the same meaning as "a 5- or 7-membered ring which may be substituted by an oxo group or a thioxo group".
- Other preferred examples of the compound represented by the formula [I] or a salt thereof include a compound represented by the formula [II
- A, a ring, C, a ring and a ring D each represent a benzene ring which may have a substituent
- X are one NR 8 —
- R 8 is a hydrogen atom or a substituent Represents a hydrocarbon group which may have a)
- U represents one (CH 2 ) m— (m represents 1 or 2) or one NH—
- R a represents a hydrogen atom or a hydrocarbon group which may have a substituent.
- a salt thereof are one NR 8 — (R 8 is a hydrogen atom or a substituent Represents a hydrocarbon group which may have a), one O— or one S—, U represents one (CH 2 ) m— (m represents 1 or 2) or one NH—, R a Represents a hydrogen atom or a hydrocarbon group which may have a substituent. Or a salt thereof.
- the substituent which the A ′ ′ ring, the C ′ ring and the D ring may have include the substituent represented by the ring A in the above formula [I]. And has the same meaning as the substituent that the cyclic hydrocarbon may have.
- a ′, and the ring represent a benzene ring which may have a substituent
- the ring Q represents an aromatic ring which may have a substituent
- W represents one CH 2 —, one CO— or One CS—, V—CH— or N— or W and V together
- Y is one CH ? —, OS CO—, one CS— or _NR ! 1
- R 9 represents a hydrogen atom or a hydrocarbon group
- U ′ is —NH—, one CH 2 — Or one CH 2 NH—
- R b represents a hydrogen atom or an optionally substituted hydrocarbon group
- ⁇ represents a single bond or a double bond. Or a salt thereof.
- A, 'and the ring represent a benzene ring which may have a substituent
- the ring Q represents an aromatic ring which may have a substituent.
- substituent on the benzene ring and the aromatic ring include (i) a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc., preferably, chlorine, fluorine, etc.), and (ii) a halogen atom.
- alkyl group which may be substituted with the halogen examples include a linear or branched alkyl group having 1 to 6 carbon atoms or a halogen atom (eg, fluorine, chlorine, bromine iodine, etc.).
- a straight-chain or branched alkyl group having 1 to 4 carbon atoms, such as isobutynole, sec-butynole, and tert-butylinole, or a group obtained by substituting 1 to 3 halogen atoms as described above is used.
- alkoxy group optionally substituted by halogen and the alkylthio group optionally substituted by halogen include, for example, the alkyl group or the alkyl group substituted by halogen, and an oxygen atom and a sulfur atom, respectively.
- An alkoxy group which may be substituted with a halogen formed by bonding, an alkylthio group which may be substituted with a halogen, and the like are used.
- alkoxy group which may be substituted with halogen examples include, for example, a linear or branched alkoxy group having 1 to 6 carbon atoms or a group obtained by substituting 1 to 5 halogen atoms as described above. Used, for example, methoxy, difluorome Toxic, trifluoromethoxy, ethoxy, 2,2,2_trifluoroethoxy, propoxy, isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isoptoxy, sec-butoxy, pentoxy, hexoxy, etc.
- methoxy, difluoromethoxy, trinoleolomethoxy, ethoxy, 2,2,2-trihnoleoethoxy, ethoxy, propoxy isopropoxy, butoxy, 4,4,4-trifluorobutoxy.
- examples thereof include a linear or branched alkoxy group having 1 to 4 carbon atoms, such as isobutoxy and sec-butoxy, or a group obtained by substituting 1 to 3 halogen atoms as described above.
- methylthio, difluoromethylthio, trifluoromethylthio, ethylthio, propylthio, isopropyl pyrthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio, hexylthio and the like are generally used, and preferably, for example, methylthio, difluoromethyl
- a straight-chain or branched alkylthio group having 1 to 4 carbon atoms such as thio, trifluoromethylthio, ethylthio, propylthio, isopropylthio, butylthio, 4,4,4-trifluorobutylthio or the above-mentioned alkylthio group; 1 to 3 halogen atoms What is replaced is used.
- Preferred examples of the substituent of the aromatic ring represented by the benzene ring represented by the ring A,,, or the ring Q include (i) a halogen atom, and (ii) an alkyl which may be substituted with a halogen. group, (ii C ⁇ 6 alkoxy group, (iv) hydroxyl, WC ⁇ 4 alkyl Le group an amino group and optionally substituted by (vi) C one 3 Ashiruokishi group, and the use Rere. (i) ⁇ ( Each term in vi) has the same meaning as described above.
- the substituents on the aromatic ring represented by the benzene ring represented by the ring A,,, or Q may be substituted on any of the substitutable positions of the benzene ring and the aromatic ring, and the number of the substituents may be two or more. May be the same or different, and the number is not 1 And preferably four or two.
- an adjacent carbon on the A ring or the Q ring is linked to a group represented by 1 (CH 2 ) 4 — (q is an integer of 3 to 5) to form a 5- or 7-membered ring.
- q is an integer of 3 to 5
- ring A preferably, for example, a nitrogen atom (eg, chlorine), a C i_ 4 alkyl group optionally substituted with 1 to 3 halogen atoms (eg, methyl, ethyl, isopyryl, trifluoromethyl) Etc.) and C j- 4 alkoxy group (for example, methoxy etc.), may be substituted with 1 to 4 substituents, and a benzene ring is used.
- one halogen as defined above
- a benzene ring which may be substituted with one alkyl group (eg, methyl, ethyl, isopropyl, etc.) is preferable.
- the aromatic ring represented by ring Q may have, for example, 1 to 4, preferably 1 or 2 oxygen, sulfur and nitrogen atoms in addition to carbon atoms, and may have 5 or 6 members And preferably a 5- or 6-membered aromatic ring which may have one or two nitrogen atoms other than a carbon atom, more preferably, for example, (1) a benzene ring, (2 ) A pyridine ring, (3) a pyrazine ring, (4) a pyrimidine ring, (5) a pyridazine ring, etc., more preferably, for example, a benzene ring or a pyrimidine ring, and particularly preferably, for example, a benzene ring, etc.
- the Q ring may have the same or different and may have 1 to 4 substituents.
- substituents include (i) halogen (eg, fluorine, chlorine, etc.), and (ii) An alkyl group optionally substituted with halogen (eg, methyl, ethyl, isopropyl, trifluoromethyl, etc.); and (iii) a 4- alkoxy group optionally substituted with halogen (eg, methoxy, ethoxy, isopropoxy).
- the hydrocarbon group represented by R 9 has the same meaning as described above.
- W represents one CH 2 —, one CO— or one CS—, preferably one CH 2 —, one CO—.
- V is.
- one CH— or one N— indicates, preferably, one CH 2 -, one ⁇ _, one CO-, -NR 9a - (R 9a is, for example, methyl, Echiru, propyl Le And C ⁇ e alkyl groups such as isopropyl, etc.), and particularly preferably —CH 2 — and 1 O—.
- U represents _NH—, one CH 2 —, _CH 2 NH—, preferably one NH—, one CH 2 —.
- a compound represented by the formula [V] 0 a compound represented by the formula [V] 0 [Wherein, R 1 () and R 11 each represent a hydrogen atom, a halogen atom, a chain hydrocarbon group which may have a substituent, or a carbon atom together with an adjacent carbon atom. May have a substituent!
- ring I is a substituted benzene ring or optionally substituted pyridine ring
- ring J is substituted A benzene ring which may be substituted or a pyridine ring which may be substituted;
- R 1 0 is water atom
- R 1 1 represents a substituted chain hydrocarbon group.
- a compound represented by or a salt thereof can be mentioned, R 1 Q and R 1 Examples of 1 include a hydrogen atom, a halogen atom, a chain hydrocarbon group which may have a substituent, a cyclic hydrocarbon which may have a substituent together with an adjacent carbon atom, or It is preferable to form a dihydrofuran ring which may be oxoated.
- R 1 . And R 1 1 may have a substituent group chain hydrocarbon group” represented by and “optionally substituted with an optionally substituted chain carbon I nonhydrogen group hydroxyl
- chain hydrocarbon group for example, an alkyl group, an alkenyl group, an alkyl group and the like are used.
- the alkyl group a linear or branched alkyl group having 1 to 7 carbon atoms is preferably used.
- the alkyl group has a carbon number of, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.
- One to four linear or branched alkyl groups are used.
- alkenyl group an alkenyl group having 2 to 6 carbon atoms such as, for example, ethenyl, propyl, isopropyl, butenyl, isobutenyl, sec-butenyl and the like are used, and preferably, for example, ethenyl, propyl, An alkenyl group having 2 to 4 carbon atoms such as isopropenyl is used.
- alkyl group examples include alkenyl groups having 2 to 6 carbon atoms, such as ethenyl, propyl, isopropynyl, butynyl, isobutenyl, sec-butul, and the like, and preferably ethynyl, propynyl, isopropynyl, and the like.
- An alkynyl group having 2 to 4 carbon atoms is used.
- chain hydrocarbon group for example, a linear or branched alkyl group having 1 to 6 carbon atoms is preferable, and particularly, methyl, ethyl, propyl, isopropyl, and butyl Preferred are linear or branched alkyl groups having 1 to 4 carbon atoms, such as toluene, isobutyl, sec-butyl and tert-butyl.
- R 1 Q and R 11 are each a halogen atom (eg, a fluorine atom, a chlorine atom, a bromine atom), an optionally substituted 7- alkyl group (preferably methyl, ethyl, propyl, etc.).
- human Dorokishiru group such as main butoxy - 4 alkoxy group
- virtuous preferred, among them halogen atom or an optionally substituted C i _ 7 alkyl group.
- alkyl group optionally having substituent (s) such as main butoxy - 4 alkoxy group
- the ⁇ 7 alkyl group '' may have an oxo group as a substituent, and when the oxo group is substituted at the ⁇ -position,
- CJ- 7 alkyl group such as formyl or acetyl.
- substituent of the C 7 alkyl group include:
- C 6 which may have 1 to 4 substituent (s) selected from 4 alkyl (eg, methyl), a halogen atom, a hydroxy group and C i_ 4 alkyl which may be halogenated ___________________________________________________________________________ 2 _ 2 _ ___________________________________ , A hydroxy group and a halogenated group. It is no substituent 1 selected from Preparative 4 alkyl may have four. 7 ⁇
- 5- to 9-members containing 1 to 3 hetero atoms such as 5 aralkyl (eg, benzyl), 4 alkoxy-C ⁇ 4 alkyl (eg, propoxicetyl, etc.), carbon atom, etc., in addition to carbon atom
- Heterocyclic groups e.g., piberidinyl, piperanidyl, morpholinyl, chel, furinole, pyridyl, pyrimidinyl, thiazolinole, benzothiazolinole, benzoisothiazolinole, benzoyloxazolinole, benzisoisoxazolyl 5 to 9-membered cyclic amino group (eg, pyrrolidinyl) which may be substituted with a hydroxyl group or the like, may contain 1 to 3 hetero atoms such as an oxygen atom and a sulfur atom in addition to a nitrogen atom , Piperidiel, piperaziny
- C 6 alkyl-carbonyloxy group for example, methylcarbonyloxy, ethylcarbonyloxy, butylcarbonyloxy, etc.
- R 11 together with an adjacent carbon atom to form a cyclic hydrocarbon which may have a substituent include, for example, a saturated or unsaturated cyclic aliphatic (for example, cycloalkyl) Alkanes, cycloalkenes, cycloalkadienes, etc.) and aryl.
- Examples of the cycloalkane include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, etc., and among them, cyclopropane, cyclobutane, cyclopentane and cycloheptane C 3 7 consequent Roarukan of hexane, and the like are preferable.
- Examples of the cycloalkene for example, cyclopentene, cyclohexene consequent opening, cyclobutene, C s _ 6 cycloalkene cyclopentene, and the levator up.
- cycloalkadiene for example, 2, 4-cyclopentadiene Jefferies emissions, 2, Kisajen to 4 consequent opening, 2, and C 5 _ 6 cycloalkanone force Zhen Kisajen the like into 5-cyclopropyl.
- aryl examples include a monocyclic or condensed polycyclic aromatic hydrocarbon having 6 to 16 carbon atoms, such as a benzene ring, a naphthalene ring, an anthracene ring, a phenanthrene ring, and an acenaphthalene ring.
- C 6 _i such as benzene ring and naphthalene ring.
- a reel is particularly preferred
- R 1 1 preferred examples of good rings Josumi I inhibit hydrogen be formed together with the carbon atom to which R 1 1 is connexion adjacent such together, include C 5 _ 7 cyclic hydrocarbon, further saturated or cyclic unsaturated Aliphatic (for example, cycloalkane, cycloalkene, cycloalkadiene, etc.); and particularly, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, etc., among which cyclopropane, cyclobutane , cyclopentane, C 3 7 cycloalkane such as hexa down cyclohexylene is preferred.
- Aliphatic for example, cycloalkane, cycloalkene, cycloalkadiene, etc.
- the substituent which the cyclic hydrocarbon may have has the same meaning as the substituent in the aforementioned "hydrocarbon group which may have a substituent".
- the above-mentioned unsaturated cyclic aliphatic substituent is preferably an oxo group or a hydroxyl group.
- a benzene ring optionally having a substituent represented by ring I a pyridine ring optionally having a substituent
- a substituent represented by ring J May
- the substituents on the benzene ring and the optionally substituted pyridine ring have the same meanings as the substituents on the “optionally substituted cyclic hydrocarbon group” represented by the ring A. Have.
- Ring I is preferably a benzene ring optionally substituted with an alkyl group, a halogenated alkyl group or a halogen atom, and may be substituted with a C ⁇ 6 alkyl group, a halogenated ⁇ ⁇ 4 alkyl group or a halogen atom. Redbenzene rings are particularly preferred.
- J ring optionally benzene ring are preferred optionally substituted with a halogenated alkyl group or a C port plasminogen atoms
- a benzene ring which may be substituted with a halogenated Ji DOO 4 alkyl group or a halogen atom is particularly preferred.
- Preferred examples of the compound or a salt thereof represented by the formula (I) include:
- R 12 and R 13 each represent a hydrogen atom, a halogen atom or a chain hydrocarbon group which may have a substituent, or a substituent together with an adjacent carbon atom to form a substituent. May form a cyclic hydrocarbon which may have,
- R 13 is not a methyl group
- R 13 is not a chlorine atom.
- the cyclic hydrocarbon which may have a substituent which R 12 and R 13 together may form together with an adjacent carbon atom is the above-mentioned R 1 .
- R 11 may be formed together with a carbon atom to be bonded together, and have the same meaning as “a cyclic hydrocarbon which may have a substituent”.
- C 5 _ 7 cyclic hydrocarbon elevation Gerare further saturated or unsaturated (E.g., cycloalkane, cycloalkene, cycloalkadiene, etc.), and especially cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, and the like.
- cyclopropane, cyclobutane, cyclopentyl lanthanum, C 3 _ 7 cycloalkane cyclohexane and the like cycloalkyl are preferred.
- R 12 and R 13 are each preferably a halogen atom or a C 1-3 alkyl group.
- the “substituent” in the optionally substituted phenyl group represented by is the same as the “substituent” in the optionally substituted benzene ring represented by ring I above. .
- a preferable example of is a phenyl group which may be substituted with an alkyl group.
- the “benzene ring optionally having substituent (s) and the pyridine ring optionally having substituent (s)” represented by ring L are the “substituted ring” represented by ring J above.
- L ring examples include a substituted benzene ring.
- the substituent may have the same meaning as the substituent, which may be possessed by the L ring.
- the compounds represented by the formulas [I], [II], [III], [IV], [V] and [VI] may be in the form of a free form or a pharmacologically acceptable salt.
- a pharmacologically acceptable salt include.
- an inorganic base For example, alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, transition metals such as zinc, iron, and copper
- organic bases for example, alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, transition metals such as zinc, iron, and copper
- N, N'—Organic amines such as dibenzylethylenediamine, and basic amino acids such as arginine, lysine, orditin and the like may be formed.
- a basic group such as an amino group, an inorganic acid or an organic acid (eg, Hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, carbonic acid, bicarbonate, formic acid, acetic acid, propionic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, cunic acid, succinic acid, malic acid, methanesulfonic acid, benzene phenol Fonic acid, p-toluenesulfonic acid, etc.)
- a salt with an acidic amino acid such as spargic acid or glutamic acid may be formed.
- the compounds represented by the formulas [I], [II], [III], [IV], [V] and [VI] or salts thereof can also be used as prodrugs.
- the prodrug is a compound represented by the formula (I), (II), (III), (IV), (V) or (VI) by a reaction with an enzyme or stomach acid under physiological conditions in a living body. Is a compound that can be converted into its salt, that is, represented by the formulas (I), (II), (III), (IV), (V) and (VI) by enzymatically oxidizing, reducing, hydrolyzing, etc.
- a compound or a salt thereof which is converted into a compound or a salt thereof, or is hydrolyzed by stomach acid or the like to give a compound represented by the formula (I), (II), (III), (IV), (V) or (VI) or a salt thereof.
- Examples of the prodrugs of the compounds represented by the formulas (I), (II), (III), (IV), (V) and (VI) or salts thereof include formulas (I), (II), (III), When the compound represented by [IV], [V] or [VI] or a salt thereof has an amino group, a compound in which the amino group is acylated, alkylated or phosphorylated (for example, formulas [I], [I] II), [III], [IV], [V] and [VI] or a salt thereof, wherein the amino group is eicosanoylated, alanylated, pentylaminocarboxylated, (5-methyl-2-oxo) (1,1,3-dioxolen-14-yl) methoxycarbonylation, tetrahydrofurininoleido, pyrrolidylmethylation, viva- mouthyloxymethylation, tert-butylethylated compounds, etc.); Formulas [I] and
- prodrugs of the compounds represented by the formulas [I], [II], [III], [IV], [V] and [VI] or salts thereof are described in Hirokawa Shoten 1990, “Development of Pharmaceutical Products”, No. 7. Compounds represented by the formulas (I), (II), (III), (IV), (V) and (VI) under physiological conditions as described on page 163 to 198 It may change to salt.
- the compound represented by the formulas (I), (II), (III), (IV), (V) and (VI) or a salt thereof may be any of hydrates and non-hydrates.
- the compounds represented by the formulas [I], [II], [III], [IV], [V] and [VI] or salts thereof are isotopes (eg,% 1 C, 35 S, 125 I, etc.) It may be marked as such.
- Preferred examples of the compound represented by the formula (I) include, in addition to the compounds represented by the formulas (II) to (VI), for example, EPA 585913, EPA602598, JP-A-6-263736, The compounds disclosed in JP-A-6-340647, JP-A-8-295667 and WO 99-33825 are exemplified.
- the compounds represented by the formula (I) include, in addition to the compounds represented by the formulas (II) to (VI), for example, EPA 585913, EPA602598, JP-A-6-263736, The compounds disclosed in JP-A-6-340647, JP-A-8-295667 and WO 99-33825 are exemplified.
- the compounds represented by the formula (I) include, in addition to the compounds represented by the formulas (II) to (VI), for example, EPA 585913, EPA602598, JP-A-6-263736, The compounds disclosed in JP-A-6-3
- the compound represented by the formula [I] and a salt thereof include known compounds and novel compounds.
- the known compounds [II], [III] and [IV] and salts thereof are described, for example, in EP A 585 913, EP A 620 598, JP-A-6-26373.
- the new compounds [V] and [VI] and salts thereof can be produced, for example, by the following method. That is, the compound [I] or a salt thereof can be produced by the above-mentioned known method capable of producing the compounds [II], [III] and [IV], the conjugates [V] and [V I] can be produced by the following production methods and methods analogous thereto.
- the compound [V] or a salt thereof is, for example, as shown in the following formula, a corresponding coumarin acetic acid derivative [V I I], a salt thereof or a reactive derivative of a carbonyl group thereof with a compound [V I I]
- Examples of the reactive derivative of the carboxylic acid include acid anhydrides (eg, chloride, bromide, etc.), acid anhydrides, mixed acid anhydrides (eg, anhydrides with methyl carbonic acid, anhydrides with ethyl carbonic acid, isobutyl carbons).
- active esters eg, esters with hydroxysuccinimide, esters with 1-hydroxybenzotriazole, esters with N-hydroxy-15-norbonorenene-1,2,3-dicarboximide, p Esters with 12-trofenol, estenol with 8-oxyquinoline, and the like are used, and acid peroxides are particularly preferred.
- Compound (V) or a salt thereof can also be produced by reacting a coumarinacetic acid derivative (VII) or a salt thereof with a compound of the formula (VIII) or a salt thereof in the presence of a coupling reagent.
- a coupling reagent include carbodiimides (for example, dicyclohexylcarbodiimide, N- [3- (dimethylamino) propyl] - ⁇ '-ethylethylcarbodiimide, ⁇ -cyclohexyl- ⁇ ') -
- the reaction is usually carried out in a solvent that does not adversely affect the reaction (for example, chloropho / rem, dichloromethane, ethyl ether, tetrahydrofuran, dioxane, dimethyloxetane, ethyl acetate, benzene, toluene, pyridine, N, N-dimethylformamide, etc.). Hydrocarbons, ethers, esters, hydrocarbons, aromatic amines, amides, etc.). This reaction can be performed in the presence or absence of a base.
- the reaction temperature is usually about 110 ° C to 120 ° C, preferably about 0 ° C to 100 ° C.
- the reaction time is usually about 5 minutes to 48 hours, preferably about 0.5 to 24 hours.
- the amount of compound [VIII] or a salt thereof used is about 1 to 1 mol of compound [VII] or a salt or a reactive derivative thereof. 5 molar equivalents, preferably about 1 to 3 molar equivalents.
- the base include alkylamines such as triethylamine, cyclic amines such as N-methylmorpholine and pyridine, aromatic amines such as N, N_dimethylaline, N, N-getylaniline, sodium carbonate and potassium carbonate. Alkali metal carbonate, sodium bicarbonate, alkali metal bicarbonate such as hydrogen bicarbonate, etc.
- the coupling reagents are used in an amount of about 1 to 5 molar equivalents per mole of compound [VIII] or a salt thereof. It is preferably about 1 to 3 molar equivalents.
- water may be added to the reaction system in an appropriate ratio to cause a two-phase reaction.
- a coupling reagent it is usually preferable to carry out the reaction under anhydrous conditions.
- the amount of the coupling reagent to be used is about 1 to 10 molar equivalents, preferably about 1 to 3 molar equivalents, per 1 mol of compound [VII] or a salt thereof.
- the amount is about 1 to 5 molar equivalents, preferably about 1 to 2 molar equivalents, per 1 mol of the coupling reagent.
- the starting compound [VII] or a salt thereof used in the above reaction can be obtained, for example, by the method described in EPA 5859913 or a method analogous thereto.
- the starting compound [VII] or a salt thereof can also be obtained by the following method.
- R c represents an alkyl group (methyl, ethyl, propyl, t-butyl, etc.), and other symbols have the same meanings as described above.
- the reaction step 1 is carried out by condensing the compound [ ⁇ ] or a salt thereof with a reactive derivative of succinic acid monoester.
- Examples of the reactive derivative of the succinic acid monoester include, for example, an acid peroxide (for example, acid chloride) of a monoalkyl ester succinate (eg, methinolestaine, ethinolestaine, propinolestaine). , And ethyl succinate chloride are particularly preferred.
- the amount of the reactive derivative of the succinic acid monoester used is usually from an equimolar amount to about 10-fold molar amount with respect to the compound [ ⁇ '] or a salt thereof, preferably from an equimolar amount to 3 times. It is used in a double molar amount.
- the reaction is usually advantageously performed in the presence of a base, and an organic or inorganic base is used as the base.
- an organic base for example, tertiary amines (for example, triethylamine, disopirpyruethylamine, diazabisikopendecene, etc.) and the like are used.
- the inorganic base include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, and hydroxylated lime; alkali metal carbonates such as sodium carbonate, carbonated lime and cesium carbonate; sodium hydrogen carbonate and hydrogen carbonate Force Alkali metal bicarbonate such as aluminum; sodium hydride, alkali metal hydride such as hydrogenation power, etc. are used.
- the amount of the base to be used is generally an equimolar amount to about 10-fold molar amount, preferably an equimolar amount to 3-fold molar amount, relative to the compound [ ⁇ '] or a salt thereof.
- the reaction can be advantageously performed in a solvent.
- a solvent that does not adversely affect the reaction is used.
- the solvent include hydrocarbons (eg, pentane, hexane, cyclohexane, benzene, toluene, etc.), and halogenated hydrocarbons.
- ethers for example, methyl ether, tetrahydrofuran, dioxane, etc.
- amides for example, ⁇ , ⁇ -dimethylformamide, hexamethylphosphoric triamide, etc.
- nitriles eg, acetonitrile, propionitrile, etc.
- the amount of the solvent to be used is generally about 1 to 100 milliliters, preferably about 10 to 50 milliliters, per gram of compound [ ⁇ ] or a salt thereof.
- the reaction temperature is usually about 120 ° C to the boiling point of the solvent used in the reaction, and preferably about 25 ° C to 100 ° C.
- the reaction time is about 10 minutes to 24 hours, preferably about 20 minutes to 12 hours, depending on the type of base and reaction solvent used and the reaction temperature.
- Reaction step 2 is performed by treating compound [ ⁇ ] with a base.
- a base for example, the same base as described in the reaction step 1 is used, and the amount of the base used is usually about 0.1-fold molar amount to the compound [VII "] or a salt thereof. It is a 10-fold molar amount, preferably about 0.1- to 1-fold molar amount.
- the reaction can be advantageously performed in a solvent.
- a solvent that does not adversely influence the reaction is used.
- the solvent include hydrocarbons (for example, pentane, hexane, cyclohexane, benzene, toluene, etc.), and nitrogenated hydrocarbons (for example, dichloromethane, Closholm, etc.), athenoles (eg, Jech Ethers, tetrahydrofuran, dioxane, etc.), amides (eg, N, N-dimethylformamide, hexamethylphosphoric triamide, etc.), ureas (eg, 1,3-dimethyl-3,4,5,6-tetrahydro-2 (1H ) -Pyrimidine, etc.), nitriles (eg, acetonitrile, propionitrile, etc.) and the like are used.
- hydrocarbons for example, pentane, hexane, cyclohexan
- the amount of the solvent to be used is generally about 1 to 100 milliliters, preferably about 10 to 50 milliliters, per 1 gram of the compound [ ⁇ "]. Or up to the boiling point of the solvent used in the reaction, preferably about 25 ° C. to 120 ° C.
- the reaction time varies depending on the type of the base and the reaction solvent and the reaction temperature, and is about 30 minutes to 2 hours. 4 hours, preferably about 1 to 12 hours.
- the reaction can be advantageously carried out by removing water generated during the reaction using a Dien-Stark dehydrator or the like.
- reaction step 1 and the reaction step 2 can be performed at once.
- a reactive derivative of succinic acid monoester for example, succinic acid monoalkyl ester
- Acid halides eg, methyl esters, ethyl esters, propyl esters
- bases for example, tertiary amines (eg, triethylamine, disopyrupyrethylamine, diazavisic)
- the compound [VII ']] or a salt thereof can be produced from the compound [vir'] or a salt thereof at a stretch by using an excess amount of oxadecane or the like.
- the amount used is usually about 1.5 times the molar amount of the compound [ ⁇ '] or a salt thereof, and then 10 times the molar amount, preferably about 1.5 times the molar amount to 3 times the molar amount.
- the amount of the base to be used is generally about 2- to 10-fold molar amount, preferably about 2-fold molar amount, relative to compound [VII '"] or a salt thereof. What Used to 5-fold molar amount.
- the reaction can be advantageously performed in a solvent.
- a solvent that does not adversely influence the reaction is used.
- the type and amount of the solvent to be used are, for example, the same as those in the reaction step 1.
- the reaction temperature is usually about 20 ° C to the boiling point of the solvent used in the reaction, and preferably about 25 ° C to 60 ° C.
- the reaction time is acid halide ⁇ The time is about 30 minutes to 24 hours, preferably about 30 minutes to 4 hours, depending on the type of base, the type of reaction solvent, and the reaction temperature.
- Reaction step 3 is performed by treating compound [ ⁇ ′′] with an acid or a base.
- the acid examples include organic acids (eg, formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, benzenesulfonic acid, ⁇ -toluenesulfonic acid, etc.) and inorganic acids (eg, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid) , Phosphoric acid, etc.), and if necessary, two or more of them can be used by mixing at an appropriate ratio.
- organic acids eg, formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, benzenesulfonic acid, ⁇ -toluenesulfonic acid, etc.
- inorganic acids eg, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid
- Phosphoric acid e.g, Phosphoric acid, etc.
- Examples of the base include alkali metal hydroxide (eg, lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonate (eg, sodium carbonate, potassium carbonate, cesium carbonate, etc.), Alkali metal bicarbonate (eg, sodium bicarbonate, potassium bicarbonate, etc.) Strength S Used.
- the amount of the acid or base to be used is generally about 1 mol to 100 mol, preferably about 1 mol to 10 mol of the compound [ ⁇ ′ ′′].
- the reaction can be advantageously performed in a solvent.
- a solvent that does not adversely influence the reaction is used, for example, hydrocarbons (for example, pentane, hexane, cyclohexane, benzene, etc.), lower alcohols (for example, methanol, ethanol, propanol, etc.) ), Ethers (for example, acetyl ether, tetrahydrofuran, dioxane, etc.), amides (for example, ⁇ , ⁇ -dimethylinoleformamide, hexamethylphosphoric triamide, etc.), and ureas (eg, 1,3-dimethyl-3 , 4, 5, 6-tetrahydro-2 (1H) -pyrimidine, etc.).
- hydrocarbons for example, pentane, hexane, cyclohexane, benzene, etc.
- lower alcohols for example, methanol, ethanol, propanol, etc.
- the above-mentioned acid can be used as a solvent.
- solvents can be used alone, or, if necessary, two or more of them can be mixed at an appropriate ratio or used as a mixed solvent with water.
- the amount of the solvent to be used is generally about 1 to 100 milliliters, preferably about 10 to 50 milliliters per gram of the compound [ ⁇ ′′].
- the reaction temperature is usually about 120 ° C.
- the temperature is up to the boiling point of the solvent used in the reaction, and is preferably about 15 ° C. to 120 ° C.
- the reaction time depends on the type of the acid, the reaction solvent, and the reaction temperature, and is about 10 minutes to 2 minutes. 4 hours, preferably about 30 minutes to 12 hours.
- the coumarinamide condensed with the oxo-modified cycloalkane can also be synthesized by subjecting the coumarinamide condensed with the cycloalkane to an oxidation reaction at an appropriate stage of the synthesis.
- the oxidation reaction is carried out using an oxidizing agent (eg, permanganate, chromate, etc.) by a method known per se [eg, AB Smith, III, et. Al., The Journal et al. This is performed by using the method of "Buy Ogak 'Chemistry" (The Journal of Organic Chemistry, vol. 50, pp. 3239-3241, 1985).
- the same salts as the salts of the aforementioned compound [I] are used.
- the compound [VI] or a salt thereof can be produced, for example, by the following method (1) or (2).
- the reaction between the carboxylic acid represented by the formula [IX] or a salt thereof or a reactive derivative thereof and the formula [X] or a salt thereof is a formation reaction of an amide bond or a perylene bond, and is carried out by various known methods.
- compound [IX] or a salt thereof eg, an alkali metal such as sodium, potassium, magnesium, or an alkaline earth metal
- a salt thereof with a compound [X] or a salt thereof eg, a salt with an inorganic acid such as hydrochloric acid or sulfuric acid, or an organic acid such as methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, oxalic acid, fumaric acid, or maleic acid
- a suitable condensing agent is used, or the compound [IX] or a salt thereof is introduced into a reactive derivative thereof and then reacted with the compound [X] or a salt thereof. Is preferred.
- a condensing agent for example, dicyclohexyl carpimide, 1_ (3-dimethylaminopropyl) -13-ethylcarbodiimide hydrochloride, getyl cyanophosphate, diphenylphosphoryl azide and the like are used.
- solvents that do not adversely influence the reaction eg, tetrahydrofuran, dioxane, dimethyloxetane, ethynole acetate, dichloromethane, 1,2-dichloroethane, benzene, toluene, N, N-dimethylformamide, dimethyl Ethers such as sulfoxides, estenoles, halogenated hydrocarbons, hydrocarbons, amides, sulfoxides, etc.).
- This reaction may be promoted in the presence of a base, and the reaction is carried out at about 10 ° C to 100 ° C, preferably at about 0 ° C to 60 ° C.
- the reaction time is generally about 1 to 96 hours, preferably about 1 to 72 hours.
- the amount of the compound [IX] or a salt thereof and the condensing agent is about 1 to 5 molar equivalents, preferably about 1 to 3 molar equivalents, per 1 mol of the compound [X] or a salt thereof.
- the base include alkylamines such as triethylamine, and cyclic amines such as N-methylmorpholine and pyridine.
- the amount of the base used is about 1 to 5 molar equivalents relative to 1 mol of the compound [IX] or a salt thereof. It is preferably about 1 to 3 molar equivalents.
- Examples of the reactive derivative of the compound (IX) include acid nodules (for example, chloride and bromide), acid anhydrides, and mixed acid anhydrides (for example, an anhydride with methyl carbonic acid, an anhydride with ethyl carbonic acid). Products, anhydrides with isobutyl carbonate, etc.), active esters (eg, esters with imidoxysuccinic acid imide, esters with 1-hydroxybenzotriazole, N-hydroxy-15-norporene-1,2,3- Esters with dicarboximide, esters with p-nitrophenol, and esters with 8-oxyquinoline).
- acid nodules for example, chloride and bromide
- acid anhydrides for example, acid anhydrides
- mixed acid anhydrides for example, an anhydride with methyl carbonic acid, an anhydride with ethyl carbonic acid.
- active esters eg, esters with imid
- Reactivity of compound [IX] or its salt with compound [X] When reacting with a derivative, usually a solvent (for example, chloroform, dichloromethane, 1,2-dichloroethane, ethyl ether, tetrahydrofuran, dioxane, dimethyloxetane, ethyl acetate, benzene, toluene, pyridine, N, N-dimethylformamide, etc.) Halogenated hydrocarbons, ethers, esters, hydrocarbons, amides, etc.). This reaction may be accelerated in the presence of a base.
- the reaction temperature is usually about 110 ° C to 120 ° C, preferably about 0 ° C to 100 ° C.
- the reaction time is usually about 0.5 to 48 hours, preferably about 1 to 24 hours.
- the amount of compound [X] or a salt thereof to be used is about 1 to 5 molar equivalents, preferably about 1 to 3 molar equivalents, per 1 mol of the reactive derivative of compound [IX].
- alkylamines such as triethylamine, cyclic amines such as N-methylmonorepholine and pyridine, aromatic amines such as N, N-dimethylaniline, N, N-ethylaniline, sodium carbonate, carbonic acid
- Alkali metal carbonates such as lime, sodium bicarbonate, and alkali metal bicarbonates such as hydrogen bicarbonate are used in amounts of 1 mol of compound [IX] or its reactive derivative. It is about 1 to 5 molar equivalents, preferably about 1 to 3 molar equivalents.
- water may be added to the reaction system at an appropriate ratio, and the reaction may be performed in a two-phase system.
- This method uses the compound [XI], which is an amine derivative, or a salt thereof (eg, a salt with a mineral acid such as hydrochloric acid or sulfuric acid, or methanesnoleic acid, benzenesulfonic acid, toluenesulfonate, oxalic acid, fumaric acid, maleic acid, etc. A salt with an organic acid) and a compound [ ⁇ ], which is an isocyanate derivative, to produce an urea derivative.
- a peria derivative is formed by a reaction using the isocyanate compound [XII] and the compound [XI] or a salt thereof. It is also effective to carry out this reaction in a solvent that can be used without using a solvent.
- the strong solvent may be any solvent as long as it does not interfere with the reaction, such as ethers (eg, ethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxetane, etc.), aromatic hydrocarbons (eg, benzene, toluene, xylene) ), Esters (eg, methyl acetate, ethyl acetate, etc.), amides (eg, ⁇ , ⁇ -dimethylformamide, etc.), sulfoxides (eg, dimethyl sulfoxide, etc.) are preferably used.
- ethers eg, ethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxetane, etc.
- aromatic hydrocarbons eg, benzene, toluene, xylene
- Esters eg
- the reaction can be advantageously advanced by adding a desalting agent, if necessary.
- a desalting agent for example, tertiary amines such as trimethylamine, triethylamine, and ⁇ -methylmorpholine, and aromatic amines such as pyridine, picoline, and ⁇ , ⁇ ⁇ ⁇ ⁇ -dimethylaniline are preferably used.
- the amount of these desalting agents used is 1 mole of the salt of compound [XII]. It is about 1 to 5 molar equivalents, preferably about 1 to 3 molar equivalents.
- the reaction temperature is generally about 110 ° C to 180 ° C, preferably about 0 ° C to 120 ° C.
- the reaction time is generally about 15 minutes to 40 hours, preferably about 30 minutes to 20 hours.
- the amount of compound [XII] or a salt thereof to be used is about 1 to 5 molar equivalents, preferably about 1 to 3 molar equivalents, per 1 mol of compound [XI] or a salt thereof.
- the starting compounds [IX], [XI] or salts thereof used in the above reaction can be obtained, for example, by the method described in EP A 620 598 or a method analogous thereto.
- the starting compound has an amino group, a carboxyl group, or a hydroxy group as a substituent.
- a protecting group commonly used in peptide chemistry or the like may be introduced into these groups, and the target compound may be obtained by removing the protecting group as necessary after the reaction. it can.
- Examples of the protecting group for the amino group include formyl, which may have a substituent,
- C ⁇ - 6 alkylcarbonyl - Honoré e.g., Asechiru, such as E chill carbonyl
- phenylene Rukarupoeru C alkyl one Okishikarubo - Le (e.g., main Tokishikarubo sulfonyl, E butoxycarbonyl, etc.), phenylalanine O carboxymethyl carbonylation Honoré, c 7 - 1 0
- Araru kill one force Ruponiru e.g., benzyl carbo - such as Le
- trityl phthaloyl or N, such as N- dimethylaminomethylene is used.
- a halogen atom for example, fluorine, chlorine, bromine, iodine, etc.
- an alkyl-carbonate for example, methylcarbonyl, ethylcarbonyl, pentinolecarbonyl, etc.
- the number of substituents is about 1 to 3.
- the protecting group of the carboxyl group for example, may have a substituent group, ⁇ _ 6 alkyl (e.g., methyl, Echiru, n- propyl, i one propyl, n- Bed chill, tert- butyl, etc.), Phenyl, trityl or silyl is used.
- substituents examples include a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), formyl, C 6 alkyl-carbinole (eg, acetyl, ethylcaprol, butylcarbonyl, etc.), and a nitro group. Used, the number of substituents is 1 Or about three.
- hydroxy-protecting group examples include, but are not limited to, 6- alkyl (eg, methyl, ethyl, n-propyl, i-propyl, n-butyl, tert-butyl, etc.), and Le, C. Ararukiru (e.g., benzyl etc.), formyl, alkyl one carbonyl (e.g., Asechiru, Echirukarubo - such as Le), phenylalanine O alkoxycarbonyl, Benzoiru, C 7 _ 1 0 Ararukiru one carbo - Le (e.g., benzyl carbo - Le ), Bilanyl, furanyl or silyl.
- 6- alkyl eg, methyl, ethyl, n-propyl, i-propyl, n-butyl, tert-butyl, etc.
- Le C. Ararukiru (e.g.,
- substituents examples include halogen atom (e.g., fluorine, chlorine, bromine, iodine, etc.), alkyl (e.g., methyl, Echiru, n- propyl, etc.), phenyl, Ji 7-1 1 0 Ararukiru (e.g., benzyl And nitro groups are used, and the number of substituents is about 1 to 4.
- halogen atom e.g., fluorine, chlorine, bromine, iodine, etc.
- alkyl e.g., methyl, Echiru, n- propyl, etc.
- phenyl e.g., Ji 7-1 1 0
- Ararukiru e.g., benzyl And nitro groups are used, and the number of substituents is about 1 to 4.
- a method for removing the protecting group a method known per se or a method analogous thereto can be used. Examples thereof include an acid, a base, reduction, ultraviolet light, hydrazine, phenylhydrazine, sodium N-methyldithiolrubamate, and tetrabutyl. A method of treating with ammonium fluoride, palladium acetate or the like is used.
- the compound [V], [VI] or a salt thereof obtained by the above method can be isolated and purified by a conventional separation means such as recrystallization, distillation, chromatography and the like.
- a conventional separation means such as recrystallization, distillation, chromatography and the like.
- the compound [V] or [VI] of the present invention obtained by force is obtained in a free form, it can be converted to a salt by a method known per se or a method analogous thereto (for example, neutralization).
- a salt when it is obtained in the form of a salt, it can be converted into a free form or another salt by a method known per se or a method analogous thereto.
- Acute coronary syndrome such as stable angina, peripheral artery occlusion, restenosis after percutaneous coronary angioplasty (PTCA), myocardial infarction, ischemic heart disease such as angina It is useful for the prevention or treatment of illness, arteriosclerosis, intermittent claudication, stroke (cerebral infarction, cerebral embolism, cerebral hemorrhage, etc.), rattan infarction, cerebrovascular dementia, etc., and is also useful as a defoamer.
- PTCA percutaneous coronary angioplasty
- novel compounds [V], [VI] and salts thereof have an ACAT inhibitory activity similarly to the known compounds [I], [II], [III], [IV] and salts thereof.
- ACAT inhibitory activity on macrophages and ACAT inhibitory activity on subtype 1 have low toxicity and safety like [I], [II], [III], [IV] and salts thereof.
- the novel compounds [V], [VI], their salts, and their prodrugs are highly available in mammals (eg, mice, rats, rabbits, dogs, cats, cattle, pigs, monkeys, humans, etc.).
- the safe prevention of cholesterolemia, atherosclerosis, and diseases caused by them for example, ischemic heart disease such as myocardial infarction and cerebrovascular disease such as cerebral infarction and stroke).
- [I], [II], [III], [IV] are used in the same manner as their salts and their prodrugs.
- an agent for inhibiting the progression of atherosclerotic lesions comprising a compound having a lipid 'rich' plaque regression action or a salt thereof (preferably, the compound of the present invention).
- the agent is preferably used in combination with an HMG-CoA reductase inhibitor.
- the compounds of the present invention may be used alone for treatment or as other lipid-lowering or cholesterol-lowering drugs, cardioprotective drugs, drugs for treating coronary artery disease, drugs for treating diabetes, thyroid function It may be used with other pharmaceutical ingredients, including anti-hypertensive, nephrotic syndrome, osteoporosis or chronic renal failure drugs, where these compounds are preferably administered as oral preparations, If necessary, it may be administered in the form of a suppository as a rectal preparation.
- Possible combinations in this case include, for example, fibrates (eg, clofibrate, bezafibrate, gemfiprodil, etc.), nicotinic acid, and derivatives thereof (eg, asipimottas and probucol) , Bile acid binding resin [eg, cholestyramine, colestipol, etc.], compounds that inhibit cholesterol absorption [eg, cytosine Sterol and neomycin etc.), compounds that inhibit cholesterol biosynthesis [eg, HMG-CoA reductase inhibitors such as oral pastatin, simpastatin, prapastatin], squalene epoxidase inhibitors [eg, NB-59] 8 and related products).
- fibrates eg, clofibrate, bezafibrate, gemfiprodil, etc.
- nicotinic acid eg, asipimottas and probucol
- Bile acid binding resin eg,
- Yet another possible combination component is an oxidosqualene-lanosterol cyclase, such as a decalin derivative, an azadecalin derivative and an indane derivative.
- antidiabetic drugs [actos, rosiglidason, kinedac, benfil, hyumulin, eudarcon, glimicron, daoneil, noporin, monotard, insulins, darcobium, dimerin, lastinone, basilcon, demerin S, isgillin];
- Antihypertensive agent [Dry thyroid (thyreoid), repothyroxine sodium (tyradin S), liothyronidine sodium (si ⁇ nin, thyromin);
- prednisolone prednisolone
- prednisolone sodium succinate prednin
- prednin prednisolone sodium succinate
- methylprednisolone sodium succinate prednisolone sodium succinate
- the compound of the present invention is suitable for the prevention and treatment of thrombus formation in view of the lipid / litz / plaque regression of the compound of the present invention. They may be used alone or in combination with the following known therapeutic agents, preferably by oral administration.
- Antithrombotic drug Anticoagulant [eg, Heparin sodium, Heparinka
- thrombolytic Drugs eg, tPA, perokinase
- antiplatelet drugs eg, aspirin, sulfinpyrazolo (anturane), dipyridamole (persanthin), ticlopidine (panaldine), cilostazol (pletal), GP IIb / IIIa antagonist (leopop)
- Coronary vasodilators diphedipine, diltiazem, nicorazil, P nitrite; cardioprotective drugs: oral drugs for cardiac ATP-K, endothelin antagonists, perotinsin antagonists, etc.
- the compound of the present invention can be used orally or parenterally by injection, infusion, inhalation, immediate injection, or topical administration. Granules, tablets, pills, capsules, capsules, injections, syrups, emulsions, elixirs, suspensions, solutions, etc.).
- compositions can be formulated according to the usual methods. Such preparations can usually be produced by mixing / kneading the active ingredient with additives such as excipients, diluents and carriers.
- parenteral includes subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, infusion and the like.
- injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be prepared using a suitable dispersing or wetting agent and suspending agent in a manner known in the art.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as an aqueous solution.
- acceptable vehicles or solvents include water, Ringer's solution, isotonic saline and the like.
- sterile fixed oils may conventionally be employed as a solvent or suspending medium.
- non-volatile oils and fatty acids can be used, including natural or synthetic or semi-synthetic fatty oils or fatty acids, and natural, synthetic or semi-synthetic mono-, di- or triglycerides.
- Suppositories for rectal administration include the drug and a suitable nonirritating excipient, such as cocoapa It can be manufactured by mixing with polyethylene glycols, which are solid at normal temperature, but liquid at the temperature of the gastrointestinal tract and melt in the rectum to release the drug.
- a suitable nonirritating excipient such as cocoapa It can be manufactured by mixing with polyethylene glycols, which are solid at normal temperature, but liquid at the temperature of the gastrointestinal tract and melt in the rectum to release the drug.
- a suitable base eg, butyric acid polymer, glycolic acid polymer, butyric acid-glycolic acid copolymer, mixture of butyric acid polymer and glycolic acid polymer, polyglycerol fatty acid ester, etc. It is also effective to produce a sustained-release preparation in combination with the above.
- solid dosage forms for oral administration include those described above such as powders, granules, tablets, pills, and capsules.
- Formulations in such a dosage form comprise the active ingredient compound and at least one excipient, for example, sucrose, lactose (latatose), cellulose sugar, mannitol (D-man-tol), maltitol, dextran, starch.
- microcrystalline cellulose agar, alginate, chitin, chitosan, pectin, tragacanth gum, gum arabic, gelatin, collagen, casein, albumin, synthetic or semi-synthetic It can be produced by mixing and / or kneading with polymers or glycerides.
- Such dosage forms may also comprise, as usual, further additives, such as inert diluents, lubricants such as magnesium stearate, parabens, preservatives such as sorbic acid, ascorbic acid , ⁇ -tocopherol, cysteine and other antioxidants, disintegrants (eg, croscarmellose sodium), binders (eg, hydroxypropylcellulose), thickeners, buffering agents, sweeteners, Flavoring agents, perfumes and the like. Tablets and pills can additionally be prepared with enterrita coating.
- further additives such as inert diluents, lubricants such as magnesium stearate, parabens, preservatives such as sorbic acid, ascorbic acid , ⁇ -tocopherol, cysteine and other antioxidants, disintegrants (eg, croscarmellose sodium), binders (eg, hydroxypropylcellulose), thickeners, buffering agents, sweeteners, Flavoring agents
- Liquid preparations for oral administration include pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, solutions and the like, which are inert diluents commonly used in the art, such as water and It may contain additives. These oral liquid preparations can be produced according to a conventional method such as mixing the active ingredient compound with an inert diluent and, if necessary, other additives.
- the activity of the present invention is usually about 0.01 to 99 W%, preferably about 0.1 to 90 W%, usually about 0.5 to 5 OW%, depending on the dosage form. It is better to mix the component compounds.
- Dosage for a particular patient will depend on age, weight, general health, gender, diet, time of administration, mode of administration, rate of excretion, combination of drugs, and the severity of the condition the patient is treating at the time. , Depending on these and other factors.
- the lipid, litchi and plaque regression agents containing the compound of the present invention can be used safely with low toxicity, and the daily dose depends on the condition and weight of the patient, the type of compound, the administration route, etc. For example, when used as a prophylactic / therapeutic agent for hyperlipidemia, for adults (with a body weight of about 6 kg), the daily dose is about 1 as an active ingredient [I] for oral preparations.
- concomitant drug a drug obtained by combining the compound of the present invention and a concomitant drug (hereinafter abbreviated as concomitant drug),
- a lipid-rich plaque regression method which comprises administering to a mammal a combination of an effective amount of the compound of the present invention and an effective amount of a concomitant drug;
- Acute coronary artery disease such as acute myocardial infarction or unstable angina, which is administered to a mammal in combination with an effective amount of the compound of the present invention and an effective amount of a concomitant drug.
- Group peripheral arterial occlusion, restenosis after percutaneous coronary angioplasty (PTCA), hypercholesterolemia, atherosclerosis, ischemic heart disease such as myocardial infarction, cerebral infarction cerebral stroke, etc.
- Examples of the concomitant drug that can be used in combination with the compound of the present invention include, for example, a drug component other than the compound of the present invention described above, a drug for treating hyperlipidemia, a diuretic drug, a drug for treating hypertension, a drug for treating heart failure, and an arrhythmia treatment.
- Drugs anticoagulants, antiplatelet drugs, antidiabetic drugs, HDL-increasing drugs, unstable plaque stabilizers, vasodilators, vasoconstrictors, vasopressors, antibacterials, antifungals, nonsteroidal anti-inflammatory drugs , Steroids, immunomodulators, antiprotozoal drugs, anti-ulcer drugs, antitussives, antiseptic, sedatives, anesthetics, anxiolytics, antipsychotics, muscle relaxants, antiepileptics, antidepressants, narcotics antagonists Drugs, anti-tumor drugs, anti-allergic drugs, vitamin drugs, vitamins Derivatives, bones, calcium metabolism drugs, osteoporosis drugs, arthritis drugs, antirheumatic drugs, antiasthmatic drugs, pollakiuria, urinary incontinence drugs, renal failure, nephropathy drugs, atopic dermatitis drugs, allergic rhinitis Therapeutic drugs, endotoxin antagonists or antibodies
- Especially antihyperlipidemic, diuretic, hypertension, heart failure, arrhythmia, anticoagulant, antiplatelet, diabetes, HDL-enhancing drug, unstable black Stabilizers and the like are preferred.
- Specific examples of the concomitant drug other than the aforementioned pharmaceutical ingredients include the following.
- HMG-CoA reductase inhibitors eg, flupastatin, cerivastatin, atorvastatin, etc.
- fibrate drugs eg, simfibrate, clofibrate alum, clinofibrate, fenobibrate, etc.
- Anion-exchange information eg, cholestyramide, etc.
- nicotinic acid preparations eg, nicomol, niceritrol, tocopherol nicotinate, etc.
- polyunsaturated fatty acid derivatives eg, icosa pentinoate, polyenphos
- plant sterols eg, gamma-oryzanol, soysterol, etc.
- elastase dextran sodium sulfate, squalene synthase inhibitor
- CETP inhibitor 2-chloro-1-3-4-1 (2-Meth
- Thiazide diuretics (bentil hydroclothiazide, cyclopentiathiazide, ethiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, penfluthiazide, polythiazide, trichlormethiazide, etc.), loop diuretics (chlorthalidone, doclomidamid, indolidamidol , Mefluside, methicran, sotrazone, torinomid, quinetazone, metrazone, furosemide, mefurside, etc., and potassium-retaining diuretics (spironolatataton, triamterene, etc.).
- loop diuretics chlorthalidone, doclomidamid, indolidamidol , Mefluside, methicran, sotrazone, torinomid, quinetazone, metrazone, furosemide, mefurside, etc.
- alpha 2 agonists e.g., clonidine, Guano base lens, guanfacine, etc. methyldopa
- ganglionic blockers e.g., to Kisametoniumu, trimethaphan etc.
- presynaptic blockers e.g., Anoresa one Okishiron, dimethyl Aminoreserpinate, rescinamine, reserpine, syrosingopine, etc.
- neuron blocker eg, betadidine, guanethidine, etc.
- blocker eg, bunazosin, doxazosin, prazosin, terazosin, perazodil, etc.
- iS blocker eg, , Flepranolol, nadolol, chimoronole, niprazironole, bunitroronole, indenolone, penbutorone, carteolol,
- Calcium channel antagonists eg, manidipine, eucardipine, nilvadipine, nisonorepine, nitrendipine, benidipine, amlodipine, aranidipine, etc.
- phthalazine derivatives eg, butrazine, forcedralazine, ecarazine, hydralazine, todralazine, etc.
- Arasepril captopril, cilazapril, delapril, enalapril, lisinopril, temocapril, trandolapril, quinapril, imidapril, benazepril, belindopril.
- Cardiotonic drugs eg, digitoxin, digoxin, methyldigoxin, lanatoside, prossilalidine, etc.
- / 3 stimulants eg, epinephrine, norepinephrine, isoproterenol, dopamine, docarpamine, dobutamine, denopamine
- Phosphodiesterase inhibitors eg, amrinone, milrinone, olprinone hydrochloride, etc.
- Calcium channel sensitivity enhancers eg, pimobentan, etc.
- nitrates eg, pimobentan, etc.
- ACE inhibitors eg, the aforementioned ACE inhibitors, etc.
- diuretics eg, the aforementioned diuretics, etc.
- carperitide ubide carenone, vesnarinone, aminophylline, etc.
- Sodium channel blockers eg, quinidine, procarinamide, disopyramide, azimaline, cibenzoline, lidocaine, diphenylhydantoin, mexiletine, propafenone, flecainide, pirudicanide, fuetoin
- j8 blockers eg, propranolol
- Alprenolol Puetrolol
- Ox Plenolone Athenolone, Acebutronole, Metoprolonele, Bisoprolonele, Pindronore, Carteo mouth, Arlotilol, etc.
- Potassium channel blockers eg, Amiodarone
- calcium channel Verapamil verapamil, diltiazem, etc.
- Sulfonoreurea eg, tolptamide, chlorpropamide, glicloviramide, acetohexamide, tolazamide, dalibenclamide, dalibzole, etc.
- biguanide eg, metformin hydrochloride, buformin hydrochloride, etc.
- Hidalcosidase Inhibitors eg, poglipose, acarbose, etc.
- insulin sensitizers eg, pioglitazone, troglitazone, etc.
- insulin glucagon
- diabetic complications eg, epalrestat, etc.
- Dopamine dopamine denopamine and the like.
- Isodiazide Isodiazide, etamptonore (ethamptorol hydrochloride), paraaminosalicylic acid (calcium paraaminosalicylate), pyrazinamide, etyonamide, protionamide, rifampicin, streptomycin sulfate, kanamycin sulfate, cycloserin, etc.
- Tetracycline hydrochloride ampicillin, piperacillin, gentamicin, dibekacin, canendomycin, lividomycin, tobramycin, amikacin, fradiomycin, sisomicin, tetracycline, oxytetracycline, lolitetracycline, doxycycline, ampicillin, piracillin, ticaracin Noresilin, Cephalotin, Cephapilin, Cephalorizine, Cefacronole, Cephalexin, Cefloxazine, Cefadroxinole, Cephamandole, Sepoto Am, Cefuroxime, Cefotiam, Cefotiam Hexetinole, Cefloxime Xetinole, Cefudipine , Ceftazidime, cefpyramide, cefsulosin, cefmenoxime, cefpodoxime proxy Chinore, cefpirom, cefazoplan,
- cytosine antimetabolite eg, flucytosine
- Dimidazole derivatives e.g. econazole, clotrimazole, miconazole nitrate, bihonazonole, croconazonole
- Echinocandin derivatives eg, caspofungin, FK-463, V-echinocancin and the like.
- Cyclosporine tacrolimus, dasperimus, azathioprine, anti-lymphocyte serum, dried sulfonated immunoglobulin, erythropoietin, colony stimulating factor, interleukin, interferon, etc.
- Methacropromide histidine hydrochloride, lansoprazole, methoxide pramide, Pirenzepine, cimetidine, ranitidine, famotidine, pergastrin, oxesasein, proglumide, omebrazole, sucralfate, sulpiride, setraxate, gefarnato, argioxa, teprenone, prostaglandin, etc. (2 0) Zhenyin 'septum medicine
- Ephedrine hydrochloride Noseptin hydrochloride, Codin phosphate, Dihydrocodine phosphate, Isoproterenol hydrochloride, Ephedrine hydrochloride, Methylephedrine hydrochloride, Noseptin hydrochloride, Aloclamide, Chlorfuedinol, Picoperidamine, Cloperastine, Pro Tokyrol, isoprotelenole, sanolebutamol, tereptalin, oxydeteveranol, morphine hydrochloride, dextropetorphan hydrobromide, oxycodone hydrochloride, dimonolephane phosphate, tipidine hibenzanate, pentoxiverine citrate, clofedanol hydrochloride , Benzonate, guaifenesin, bromohexine hydrochloride, amproxol hydrochloride, acetyl cysteine, ethil cyst
- Chlorpromazine hydrochloride Atopin sulfate, Phenobarbital, Parpital, Amobarbital, Pentobarbital, Thiopentanole sodium, Thiamilla monosodium, Nitrazazem, Estazolam, Flurazapam, Haloxazolam, 1, Liazolam, Flunitrazazem, Brom ⁇ lem Urea, chloral hydrate, triclofos sodium, etc.
- Intravenous anesthetics eg, ketamine hydrochloride, droperidol, thiopental sodium, thiamiral sodium, pentobarbital), etc.
- Anxiolytics eg, ketamine hydrochloride, droperidol, thiopental sodium, thiamiral sodium, pentobarbital, etc.
- Chronolepromazine hydrochloride Prochronoreperazine, Trifloperazine, Thiolidazine hydrochloride, Perphenazine maleate, Flufenadine enanthate, Chlorperazine maleate, Lepomepromazine maleate, Promethazine hydrochloride, Noperoperidol, Bromperinole, Renoperinole , Clocapramine hydrochloride, sulpiride, zotepine and the like.
- Phenytoin ethosuximid, acetazolamide, chlordiazepoxide, triditadione, carbamazepine, phenobarbital, primidone, sultiam, sodium pulp oxalate, clonazepam, diazepam, nitrazepam.
- Vitamin A i Vitamin A 2 and retinol palmitate
- vitamin D vitamin have D 2, D 3, D 4 and D 5
- 3Vitamin E ⁇ -tocopherolone, j3-tocopherolone, ⁇ -tocopherolole, ⁇ -tocopherolonele, nicotinic acid dl—hitocopherol
- vitamin K Vitamin ⁇ 2, ⁇ 3 and ⁇ 4
- Vitamin D 2 derivatives such as, 6-transergocalciferonole.
- Isoprenaline hydrochloride salbutamol sulfate, propoterol hydrochloride, terbutaline sulfate, trimethoquinol hydrochloride, rlobbuterol hydrochloride, orciprenaline sulfate, Phenoterol hydrobromide, ephedrine hydrochloride, iprotropium bromide, oxytropium bromide, fino retropium bromide, theophylline, aminophylline, sodium chromoglycinate, tranilast, repirinast, anlexanone, ibudilast, ketotifen, zeftinas, zeftinas , Ozadarel hydrochloride, pranlukast hydrate, seratrodast, dexamethasone, prednisolone, hydroconorethione, beclotazone propionate, etc.
- Acute myocardial infarction, acute coronary syndrome such as unstable angina, peripheral arterial occlusion, restenosis after percutaneous coronary angioplasty (PTCA), hypercholesterolemia, atherosclerosis, myocardium Synergistic therapeutic effects are obtained for ischemic heart diseases such as infarction and angina, cerebrovascular disorders such as cerebral infarction and stroke, or diseases such as thrombus formation.
- Acute coronary syndrome such as acute myocardial infarction and unstable angina, peripheral arterial occlusion, restenosis after percutaneous coronary angioplasty (PTCA), hypercholesterolemia, atherosclerosis, myocardium
- ischemic heart disease such as infarction and angina, cerebral infarction, cerebrovascular disease such as stroke, and various diseases that occur due to diseases such as thrombus formation Demonstrate fruit.
- the administration time of the compound of the present invention and the concomitant drug is not limited, and the compound of the present invention or the pharmaceutical composition thereof and the concomitant drug or the pharmaceutical composition thereof are administered to the subject to be administered. May be administered at the same time or with a time lag.
- the dose of the concomitant drug may be in accordance with the dose clinically used, and can be appropriately selected depending on the administration subject, administration route, disease, combination, and the like.
- the administration form of the concomitant drug of the present invention is not particularly limited as long as the compound of the present invention and the concomitant drug are combined at the time of administration.
- Such administration forms include, for example, (1) administration of a single preparation obtained by simultaneously formulating the compound of the present invention and the concomitant drug, and (2) separate administration of the compound of the present invention and the concomitant drug. (3) Simultaneous administration of the two preparations obtained by the formulation via the same administration route; (3) The time difference between the same administration route of the two preparations obtained by separately formulating the compound of the present invention and the concomitant drug.
- Examples of pharmacologically acceptable carriers that may be used in the production of the concomitant drug of the present invention include various organic or inorganic carrier substances commonly used as drug substances, for example, excipients and lubricants in solid formulations. Examples include powders, binders and disintegrants, or solvents, dissolution aids, suspending agents, isotonic agents, buffers and soothing agents in liquid preparations. More If necessary, usual additives such as preservatives, antioxidants, coloring agents, sweeteners, adsorbents, and wetting agents can be used in appropriate amounts.
- Excipients include, for example, lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light caffeic anhydride and the like.
- lubricant examples include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- binder examples include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropinolemethinose / relose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, carboxy. Methyl cellulose sodium and the like can be mentioned.
- Disintegrators include, for example, starch, carboxymethylcellulose, carboxymethylcellulose calcium, potassium oleboxime / lestarinadium, L-hydroxypropylcellulose and the like.
- solvent examples include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive oil and the like.
- dissolution aid examples include polyethylene glycol, propylene glycol, D-mannitol, benzinole benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalcodium chloride, benzethonium chloride, and glyceryl monostearate; And hydrophilic polymers such as bul alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methinoresenorelose, hydroxymethinoresenorelose, hydroxyxetinoresenorelose, and hydroxypropylcellulose.
- surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalcodium chloride, benzethonium chloride, and glyceryl monostearate
- hydrophilic polymers such as bul alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methinoresenorelose, hydroxymethinoresenorelose,
- tonicity agent examples include glucose, D-sorbitol, sodium chloride, glycerin, D-mantol and the like.
- buffer examples include buffers such as phosphate, acetate, carbonate, and citrate.
- soothing agent examples include benzyl alcohol and the like.
- preservatives include paraoxybenzoates, chloroptanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite, ascorbic acid, sodium tocopherol and the like.
- the compounding ratio of the compound of the present invention and the concomitant drug in the concomitant drug of the present invention can be appropriately selected depending on the administration subject, administration, disease and the like.
- the content of the compound of the present invention in the concomitant preparation of the present invention varies depending on the form of the preparation, but is usually about 0.01 to 100% by weight, preferably about 0.01 to 100% by weight, based on the whole preparation. It is about 0.1 to 50% by weight, more preferably about 0.5 to 20% by weight.
- the content of the concomitant drug in the concomitant drug of the present invention varies depending on the form of the preparation, but is usually about 0.01 to 100% by weight, preferably about 0.1 to 5% by weight, based on the whole preparation. 0% by weight, and more preferably about 0.5 to 20% by weight.
- the content of additives such as a carrier in the concomitant drug of the present invention varies depending on the form of the preparation. Usually, about 1 to 99.9% by weight, preferably about 10 to 90% by weight, based on the whole preparation. It is about.
- the same content may be used when the compound of the present invention and the concomitant drug are separately formulated.
- These preparations can be produced by a method known per se that is generally used in the preparation process.
- the compound of the present invention or the concomitant drug may be a dispersant (eg, Tween 8).
- HC060 manufactured by Nikko Chemicals
- polyethylene glycol potassium carboxymethylsenorelose, sodium alginate, hydroxypropylmethylcellulose, dextrin, etc.
- stabilizers eg, ascorbic acid
- surfactants eg, polysorbate 80, Mac Mouth gall
- solvent eg, glycerin, ethanol, etc.
- buffering agent eg, phosphoric acid and its alkali metal salts, citric acid and its alkali metal salts, etc.
- tonicity agent eg, Shiridani sodium , Potassium salt, mannitol, sorbitol, glucose, etc.
- pH regulators eg, hydrochloric acid, sodium hydroxide, etc.
- preservatives eg, ethyl para-hydroxybenzoate, benzoic acid, methyl paraben
- the compound of the present invention or the concomitant drug is used in a manner known per se, for example, excipients (eg, lactose, sucrose, starch, etc.), disintegrants (eg, starch, calcium carbonate) ), A binder (eg, starch, gum arabic, carboxymethylcellulose, polyvinyl / repyrrolidone, hydroxypropyl senorellose, etc.) or a lubricant (eg, talc, magnesium stearate, polyethylene glycol 600) Or the like, and then compression-molded, and if necessary, coated for a taste masking, enteric or sustained purpose by a method known per se, to give a preparation for oral administration.
- excipients eg, lactose, sucrose, starch, etc.
- disintegrants eg, starch, calcium carbonate
- a binder eg, starch, gum arabic, carboxymethylcellulose, polyvinyl / repyrrol
- the coating agent examples include hydroxypropinolemethinoresenolellose, ethylcellulose, hydroxymethylcellulose, hydroxypropylsenorelose, poly (hydroxyethylene glycol), Tween 80, and Twanolonic F68. , Ce / reulose acetate phthalate, hydroxypropinolemethinoresenolerose phthalate, hydroxymethylsenorellose acetate succinate, Eudragit (manufactured by Rohm, Germany, methacrylic acid. Atari / leic acid copolymer) and dyes (Eg, Bengala, titanium dioxide, etc.).
- the preparation for oral administration may be any of an immediate release preparation and a sustained release preparation.
- the compound of the present invention or the concomitant drug can be converted into an oily or aqueous solid, semi-solid or liquid suppository according to a method known per se.
- the oily base used in the above composition include glycerides of higher fatty acids (eg, lipopolyester, witepsols (manufactured by Dynamite Nobel, Germany), etc.), and intermediate fats. Acids (eg, miglyols (Dynamite Nobel, Germany), etc.) and vegetable oils (eg, sesame oil, soybean oil, cottonseed oil, etc.).
- the aqueous base include polyethylene glycols and propylene glycol, and examples of the aqueous base include natural gums, cellulose derivatives, vinyl polymers, and acrylic acid polymers.
- sustained-release preparation examples include a sustained-release microcapsenole and the like.
- a method known per se can be used to prepare a sustained release microcapsule.
- the compound of the present invention is preferably formed into a preparation for oral administration such as a solid preparation (eg, powder, granules, tablets, capsules) or a preparation for rectal administration such as a suppository.
- a preparation for oral administration such as a solid preparation (eg, powder, granules, tablets, capsules) or a preparation for rectal administration such as a suppository.
- preparations for oral administration are preferred.
- the concomitant drug can be in the above-mentioned dosage form depending on the type of drug.
- Sublingual tablet, buccal or buccal disintegrant of the compound of the present invention or the concomitant drug and its preparation (4) Solid dispersion of the compound of the present invention or the concomitant drug and its preparation are specifically shown. .
- An injection prepared by dissolving the compound of the present invention or the concomitant drug in water is preferred.
- the injection may contain benzoate and / or salicylate.
- the injection can be obtained by dissolving the compound of the present invention or the concomitant drug and, if desired, both benzoate or Z and salicylate in water.
- salts of benzoic acid and salicylic acid include alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, ammonium salts, meglumine salts, and organic acid salts such as trometamol. .
- the concentration of the compound of the present invention or the concomitant drug in the injection is 0.5 to 50 w / v%, preferably about 3 to 20 w / v%. Also benzoate or di- and salicylate The concentration of 0.5 to 50 v%, preferably 3 to 20 w / v% is preferred. This drug also contains additives commonly used for injections, such as stabilizers
- surfactant polysorbate 80, macrogol, etc.
- solvent glycerin, ethanol, etc.
- the injection is preferably adjusted to 2 to 12, preferably 2.5 to 8.0 by adding a pH adjusting agent.
- An injection can be obtained by dissolving both the compound of the present invention or the concomitant drug and, if desired, a benzoate and / or a salicylate, and if necessary, the above-mentioned additives in water. These dissolutions may be performed in any order, and can be appropriately performed in the same manner as in the conventional method for producing an injection.
- the aqueous solution for injection is preferably heated, and can be used as an injection by subjecting it to, for example, sterilization by filtration or high-pressure heat sterilization in the same manner as an ordinary injection.
- the aqueous solution for injection is preferably sterilized by heating under high pressure at 100 ° C. to 121 ° C. for 5 minutes to 30 minutes.
- a solution having antimicrobial properties of the solution may be used so that it can be used as a multiple-dose preparation.
- a sustained-release preparation in which a core comprising the compound of the present invention or the concomitant drug is optionally coated with a coating agent such as a water-insoluble substance / swellable polymer is preferable.
- a coating agent such as a water-insoluble substance / swellable polymer
- water-insoluble substances used in the coating agent include, for example, cellulose ethers such as ethyl cellulose and butyl cellulose, cellulose esters such as cellulose acetate, cenorellospion pionate, and polybutyl esters such as polyvinyl acetate and polybutyl butyrate.
- a polymer having an acidic dissociating group and exhibiting pH-dependent swelling is preferable, and has little swelling in an acidic region such as the stomach and swells in a neutral region such as the small intestine and the large intestine. Is preferred.
- Examples of such a polymer having an acidic dissociating group and exhibiting pH-dependent swelling include, for example, Carbomer 934P, 940, 941, 974P, 980, 1342, and the like, polycarbophil, calcium polycarbophil, and the like.
- Examples of the polymer include cross-linked polyatalylic acid polymers such as finole (carcium polycarbophil) (all of which are manufactured by BF Goodrich Co., Ltd.) and Hibisco-103, 104, 105, 304 (all of which are manufactured by Wako Pure Chemical Industries, Ltd.).
- the coating agent used in the sustained-release preparation may further contain a hydrophilic substance.
- hydrophilic substance examples include polysaccharides which may have a sulfate group, such as pullulan, dextrin, and alkali metal alginate; hydroxypropylcellulose; examples include polysaccharides having a hydroxyalkyl group or a carboxyalkyl group, such as hydroxypropylmethylcellulose and sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone, polybutyl alcohol, and polyethylene glycol.
- polysaccharides which may have a sulfate group, such as pullulan, dextrin, and alkali metal alginate
- hydroxypropylcellulose examples include polysaccharides having a hydroxyalkyl group or a carboxyalkyl group, such as hydroxypropylmethylcellulose and sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone, polybutyl alcohol, and polyethylene glycol.
- the content of water-insoluble substances in the coating of sustained-release preparations is about 30 to about 90%
- the coating agent may further comprise a hydrophilic substance, in which case the content of the hydrophilic substance in the coating agent is about 50% (w / w) or less, preferably about 5 to about 40% (w / w). ), More preferably from about 5 to about 35% (w / w).
- the above-mentioned% (w / w) indicates the weight% based on the coating agent composition obtained by removing a solvent (eg, water, methanol, lower alcohol such as ethanol) from the coating agent liquid.
- a solvent eg, water, methanol, lower alcohol such as ethanol
- the sustained-release preparation a core containing a drug is prepared as exemplified below, and then the obtained core is heated and dissolved in a water-insoluble substance or swelling 'I biopolymer, or dissolved or dispersed in a solvent. It is manufactured by coating with a chemical solution.
- nucleus containing the drug to be coated with the coating agent is not particularly limited, but is preferably formed into particles such as granules or fine granules.
- the average particle size is preferably about 150 to 2
- It is preferably from about 500 ⁇ m, more preferably from about 500 to about 1,400 ⁇ m.
- the nucleus can be prepared by a usual production method.
- a drug is mixed with an appropriate excipient, binder, disintegrant, lubricant, stabilizer and the like, and the mixture is prepared by wet extrusion granulation, fluidized bed granulation, or the like.
- the drug content of the nucleus is from about 0.5 to about 95% (w / w), preferably from about 5.0 to about 80% (w / w), more preferably from about 30 to about 70% (w / w). w / w).
- the excipient contained in the core for example, sugars such as sucrose, lactose, mannitol, and glucose, starch, crystalline cellulose, calcium phosphate, corn starch and the like are used. Among them, crystalline cellulose and corn starch are preferred.
- the binder for example, polyvinyl alcohol, hydroxypropyl cellulose, polyethylene glycolone, polyvinylinolepyrrolidone, punorelonic F68, arabia gum, gelatin, fine powder and the like are used.
- Disintegrants include, for example, calcium carboxymethylcellulose calcium (ECG505), croscarmellose sodium (Ac-Di-Sol), cross-linked polyvinylpyrrolidone (crospovidone), low-substituted hydroxypropylcellulose (L-HPC ) Is used. Among them, hydroxypropylcellulose, polyvinylpyrrolidone and low-substituted hydroxypropylcellulose are preferred.
- Lubricants and anti-agglomeration agents include, for example, tanolek, magnesium stearate and its inorganic salts, and polyethylene glycol as lubricant.
- the nucleus can be prepared by spraying a binder dissolved in a suitable solvent such as water or a lower alcohol (eg, methanol, ethanol, etc.) onto the inert carrier particles serving as the core of the nucleus, in addition to the above-mentioned production method, It can also be prepared by a tumbling granulation method, a pan coating method, a fluidized bed coating method or a melt granulation method in which a small amount of a mixture of this and an excipient, a lubricant, etc. is added.
- a suitable solvent such as water or a lower alcohol (eg, methanol, ethanol, etc.)
- the inert carrier particles for example, those made of sucrose, lactose, starch, crystalline cellulose, and waxes can be used, and the average particle size is about 100 m to about 1,500 ⁇ m. Are preferred.
- the surface of the nucleus may be coated with a protective agent.
- the protective agent for example, the above-mentioned hydrophilic substances, water-insoluble substances and the like are used.
- polyethylene glycol-polysaccharide having a hydroxyalkyl group or a carboxyalkyl group is preferably used, and more preferably hydroxypropylmethylcellulose and hydroxypropylcellulose are used.
- the protective agent may contain an acid such as tartaric acid, citric acid, succinic acid, fumaric acid, and maleic acid as a stabilizer, and a lubricant such as talc. If a protective agent is used, its coverage is about 1 to about 15% (w / w), preferably about 1 to about 10% (w / w), and more preferably about 2 to About 8% (w / w).
- the protective agent can be coated by a usual coating method.
- the agent can be coated by spray coating on the core by, for example, a fluidized bed coating method or a pan coating method.
- the core obtained in the above I is coated with the water-insoluble substance and the pH-dependent swellable polymer, and a coating agent solution in which a hydrophilic substance is dissolved by heating or dissolved or dispersed in a solvent, thereby providing a sustained release.
- a formulation is manufactured.
- a method of coating the nucleus with a coating agent solution for example, a method of coating with a mist is exemplified.
- composition ratio of the water-insoluble substance, the swellable polymer or the hydrophilic substance in the coating agent solution is appropriately selected so that the content of each component in the coating becomes the above-mentioned content.
- the coating amount of the coating agent is about 1 to about 90% (w / w), preferably about 5 to about 50% (w / w) with respect to the core (not including the protective agent), and Preferably it is about 5 to 35% (w / w).
- the solvent for the coating agent solution water or an organic solvent can be used alone or in a mixture of both.
- the mixing ratio of water and organic solvent (water / organic solvent: weight ratio) when using the mixed solution can be changed in the range of 1 to 100%, and is preferably 1 to about 30%.
- the organic solvent is not particularly limited as long as it dissolves a water-insoluble substance.
- the organic solvent include lower alcohols such as methinoleanolole, ethyl alcohol, isopropyl alcohol, and n-butyl alcohol; lower alkanones such as acetone; Acetonitrile, chloroform, methylene chloride and the like are used.
- ethyl alcohol and isopropyl alcohol are particularly preferred.
- Water and a mixture of water and an organic solvent are preferably used as a solvent for the coating agent.
- an acid such as tartaric acid, citric acid, succinic acid, fumaric acid, and maleic acid may be added to the coating agent solution for stabilizing the coating agent solution.
- the operation for coating with a mist coating can be performed by a usual coating method.
- the coating agent is spray-coated on the nucleus by, for example, a fluidized bed coating method or a pan coating method.
- a fluidized bed coating method or a pan coating method can be implemented at At this time, if necessary, Tanorek, titanium oxide, magnesium stearate, Lubricants such as calcium stearate and light citric anhydride may be added, and plasticizers such as glycerin fatty acid ester, hydrogenated castor oil, triethyl taenoate, cetyl alcohol and stearyl alcohol may be added.
- an antistatic agent such as talc may be mixed as necessary.
- the immediate-release preparation may be liquid (solution, suspension, milk paste, etc.) or solid (particles, pills, tablets, etc.).
- a parenteral preparation such as an oral preparation or an injection is preferably used.
- Immediate release preparations usually contain a carrier, additives and excipients (hereinafter sometimes abbreviated as excipients) commonly used in the pharmaceutical field in addition to the active ingredient drug.
- excipients commonly used in the pharmaceutical field in addition to the active ingredient drug.
- the formulation excipient used is not particularly limited as long as it is a commonly used excipient.
- excipients for oral solid preparations include lactose, starch, corn starch, crystalline cellulose (Asacel Kasei Co., Ltd., Avicel PH101, etc.), powdered sugar, dara niyu sugar, mannitol, light anhydrous silicic acid , Magnesium carbonate, calcium carbonate, L-cysteine and the like, and preferably corn starch and mannitol.
- excipients can be used alone or in combination of two or more.
- the content of the excipient is, for example, about 4.5 to about 99.
- the content of the drug in the immediate release preparation is about 0.5 to about 9 based on the total amount of the immediate release preparation.
- It can be appropriately selected from the range of 5%, preferably from about 1 to about 60%.
- the immediate release preparation When the immediate release preparation is an oral solid preparation, it usually contains a disintegrant in addition to the above components.
- a disintegrant include, for example, lipoxymethylcellulose calcium (ECG-505, manufactured by Gotoku Pharmaceutical Co., Ltd.), croscarmellose sodium (eg, Axidisol, manufactured by Asahi Kasei Corporation), crospovidone (eg, BASF Made by Coridon C
- the amount of the disintegrating agent is appropriately selected depending on the type and amount of the drug to be used, the design of the release preparation, etc., for example, from about 0.05 to about 30 w / w ° / o , preferably from about 0.5 to about 15 w / w%.
- the oral solid preparation may contain the above-mentioned composition, and if necessary, may further contain a conventional additive in the solid preparation.
- additives include binders (for example, sucrose, gelatin, arabia gum powder, methylcellulose, hydroxypropinoresenolerose, hydroxypropylmethylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, pullulan, dextrin, etc.
- Lubricants for example, polyethylene glycol, magnesium stearate, talc, light caffeic anhydride (for example, Aerozil (Nippon Aerosil)
- surfactants for example, anion-based surfactants such as sodium anolyl sulfate, poly
- Nonionic surfactants such as oxyethylene fatty acid esters, polyoxyethylene sorbitan fatty acid esters, and polyoxyethylene castor oil derivatives, etc., coloring agents (eg, tar dyes, caramel, Gala, titanium oxide, riboflavins), if necessary, bridging agents (eg, sweeteners, flavors, etc.), sorbents, preservatives, wetting agents, antistatic agents, etc.
- Stabilizers Organic acids such as tartaric acid, citric acid, succinic acid and fumaric acid may be added.
- hydroxypropylcellulose polyethylene glycol and polybutylpyrrolidone are preferably used.
- the immediate-release preparation can be prepared by mixing the above-mentioned components, kneading and molding as necessary, based on a usual preparation production technique.
- the mixing is performed by a generally used method such as mixing and kneading.
- a method similar to the method for preparing the core of the above-mentioned sustained-release preparation can be used, such as a pericardanula and a universal kneader (manufactured by Hata Iron Works).
- the immediate-release preparations and sustained-release preparations thus obtained can be administered as they are, or separately and appropriately, together with formulation excipients, etc., in a conventional manner, and then administered simultaneously or in combination at an arbitrary administration interval.
- both may be used alone or, if appropriate, together with formulation excipients, etc., in a single oral administration formulation (eg, granules, fine granules, tablets, capsules, etc.). Both preparations can be made into granules or fine granules and filled into the same capsule, etc., to make them into preparations for oral administration.
- the sublingual tablet, buccal preparation, and quick disintegrating agent in the oral cavity may be a solid preparation such as a tablet, or may be an oral mucosal patch (Finolem).
- a preparation containing the compound of the present invention or the concomitant drug and an excipient is preferable.
- auxiliary agents such as a lubricant, a tonicity agent, a hydrophilic carrier, a water-dispersible polymer, and a stabilizer may be contained. Further, it may contain 3-cyclodextrin or a j3-cyclodextrin derivative (eg, hydroxypropyl-1-cyclodextrin, etc.) for facilitating absorption and increasing bioavailability.
- excipients examples include lactose, sucrose, D-mantol, starch, crystalline cellulose, light caffeic anhydride and the like.
- Lubricants include magnesium stearate, calcium stearate, talc, colloidal silica, and the like. Magnesium stearate colloidal silica is particularly preferred.
- the tonicity agent include sodium chloride, glucose, fmelectose, mannitol, sorbitol, lactose, saccharose, glycerin, and urea, and mannitol is particularly preferred.
- hydrophilic hydrophilic carrier examples include swellable hydrophilic carriers such as crystalline cellulose, ethylcellulose, crosslinkable polyvinylpyrrolidone, light anhydrous silicic acid, silicic acid, dicalcium phosphate, and calcium carbonate. Microcrystalline cellulose and the like) are preferred.
- Water-dispersible polymers include gums (eg, tragacanth, acacia, guar gum), alginate (eg, sodium alginate), cellulose derivatives (eg, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxypropinolecellulose, Hydroxypropyl meth Cellulose, gelatin, water-soluble starch, polyacrylic acid (eg, carboma), polymethacrylic acid, polybutyl alcohol, polyethylene glycol, polyvinylpyrrolidone, polycarbophil, ascorbic acid palmitate, and hydroxypropyl.
- gums eg, tragacanth, acacia, guar gum
- alginate eg, sodium alginate
- cellulose derivatives eg, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxypropinolecellulose, Hydroxypropyl meth Cellulose, gelatin, water-soluble starch
- polyacrylic acid eg, carboma
- methylcellulose Preferred are methylcellulose, polyacrylic acid, alginic acid salts, gelatin, carboxymethylcellulose, polyvinylpyrrolidone, polyethylene glycol and the like. Particularly, hydroxypropyl methylcellulose is preferable.
- the stabilizer include cysteine, thiosorbitol, tartaric acid, cunic acid, sodium carbonate, ascorbic acid, glycine, and sodium sulfite, and in particular, diascorbic acid citrate is preferable.
- the sublingual tablet, buccal or intraoral quick disintegrating agent can be produced by mixing the compound of the present invention or the concomitant drug with an excipient by a method known per se.
- auxiliary agents such as a lubricant, an isotonic agent, a hydrophilic carrier, a water-dispersible polymer, a stabilizing agent, a coloring agent, a sweetening agent and a preservative may be mixed.
- a lubricant such as a lubricant, an isotonic agent, a hydrophilic carrier, a water-dispersible polymer, a stabilizing agent, a coloring agent, a sweetening agent and a preservative
- a lubricant such as water or alcohol, humidifying / wetting, molding, and then drying.
- the compound of the present invention or the concomitant drug When formed into a mucosa-adhered tablet (film), the compound of the present invention or the concomitant drug, the above-mentioned water-dispersible polymer (preferably hydroxypropyl cellulose, hydroxypropylmethylcellulose), an excipient and the like are used. It is dissolved in a solvent such as water, and the resulting solution is cast into a (cast) film.
- additives such as plasticizers, stabilizers, antioxidants, preservatives, coloring agents, buffers, and sweeteners may be added.
- Glycols such as polyethylene glycol and propylene glycol can be included to give the film adequate elasticity, and bioadhesive polymers (eg, polycarbophil, lipopol) to enhance the adhesion of the film to the mucosal lining of the oral cavity ) May be included.
- bioadhesive polymers eg, polycarbophil, lipopol
- an application tool such as doctor blade
- Preferred rapid intraoral disintegrants include solid rapid forms consisting of a network of the compound or concomitant drug of the present invention and a water-soluble or water-diffusible carrier inactive with the compound or concomitant drug of the present invention. Diffusion administration agents are included.
- the network can be obtained by sublimating the solvent from the solid composition comprising the solution of the compound of the present invention or the concomitant drug in an appropriate solvent.
- composition of the intraoral quick disintegrant contains a matrix forming agent and a secondary component in addition to the compound of the present invention or the concomitant drug.
- the matrix-forming agent examples include gelatins, dextrins, animal proteins such as soybeans and barley, and psyllium seed proteins or plant proteins; gums such as gum arabic, guar gum, and xanthan for agar. Polysaccharides; alginic acids; carboxymethylcellulose; dextrans; dextrans; pectins; synthetic polymers such as polybierpyrrolidone; and substances derived from gelatin-gum arabic complex.
- saccharides such as mannitol, dextrose, ratatose, galactose and trehalose; cyclic saccharides such as cyclodextrin; inorganic salts such as sodium phosphate, sodium salt sodium and aluminum silicate; glycine, L-alanine, L-aspartic acid And L-glutamic acid, L-hydroxylproline, L-isoleucine, L-mouth isine, L-phenylalanine and the like, and amino acids having 2 to 12 carbon atoms.
- One or more of the matrix-forming agents can be introduced into a solution or suspension before solidification.
- a matrix-forming agent may be present in the form of a surfactant, or may be present with the surfactant removed.
- Matrix-forming agents are powerful in forming the matrix! In addition, it can help maintain the compound or the concomitant drug of the present invention in the state of diffusion in the solution or suspension. Secondary ingredients such as preservatives, antioxidants, surfactants, thickeners, coloring agents, pH adjusters, flavors, sweeteners or taste masking agents may be contained in the yarn. Les ,.
- Suitable colorants include red, black and yellow oxidized irons and FD & C dyes such as Ellis 'and'Everard's FD & C Blue 2 and FD & C Red 40.
- Can be Suitable flavors include mint, raspberry, licorice, orange, lemon, grapefruit, caramel, vanilla, terry and grape flavors and combinations thereof.
- Suitable pH modifiers include citrate, tartaric acid, phosphoric acid, hydrochloric acid and maleic acid.
- Suitable sweeteners include aspartame, acesulfame K and thaumatin.
- Suitable taste masking agents include sodium bicarbonate, ion exchange resins, cyclodextrin clathrates, adsorbate materials, and microforced apomorphine.
- Formulations usually contain about 0.1 to about 50% by weight, preferably about 0.1 to about 30% by weight, of a compound of the present invention or concomitant drugs, preferably for about 1 minute to about 60 minutes.
- An internal fast disintegrant is preferred.
- the content of the above-mentioned excipient in the whole preparation is about 10 to about 99% by weight, preferably about 30 to about 90% by weight.
- the content of] 3-cyclodextrin or a] 3-cyclodextrin derivative in the whole preparation is 0 to about 30% by weight.
- the content of the lubricant in the whole preparation is about 0.01 to about 10% by weight, preferably about 1 to about 5 weight. / 0 .
- the content of the tonicity agent in the whole preparation is about 0.1 to about 90% by weight, preferably about 10 to about 70% by weight.
- the content of the hydrophilic carrier in the whole preparation is about 0.1 to about 50% by weight, preferably about 10 to about 30% by weight.
- the content of the water-dispersible polymer in the whole preparation is about 0.1 to about 30% by weight, preferably about 10 to about 25% by weight.
- the content of the stabilizer in the whole preparation is about 0.1 to about 10% by weight, preferably about 1 to about 5% by weight.
- the formulation further comprises a colorant, Additives such as sweeteners and preservatives may be contained as necessary.
- lipid-rich plaque regression substance When the compound of the present invention (hereinafter sometimes referred to as lipid-rich plaque regression substance) or the concomitant drug is poorly water-soluble or insoluble, a solid dispersion (eg, poorly water-soluble or insoluble lipid 'rich' plaque) A solid dispersion containing a regression substance and a hydrophilic polymer).
- the “solid dispersion” refers to a solid inert carrier (eg, a hydrophilic polymer) or a matrix thereof which can be prepared by, for example, a melt method, a solvent method, or a melt-one solvent method.
- a dispersion in which one or more active ingredients preferably an amorphous active ingredient
- the average particle size of the solid dispersion is not particularly limited, but usually, the lower limit is about 0.05 / zm or more, preferably about 0.1 ⁇ or more, more preferably about 1 m or more, and still more preferably.
- the hydrophilic polymer used in the solid dispersion for example, a water-soluble polymer, an enteric polymer, a gastric polymer, or the like is used, and among them, an enteric polymer is preferably used.
- water-soluble polymer examples include: (1) hydroxy phenolic cellulose such as hydroxypropylcellulose and hydroxypropinolemethylcellulose; cellulose derivatives such as alkylcellulose such as methylinoresinose and ethylcellulose; and polyalkylene such as polyvierdon. Ninorpyrrolidone; (3) Polyalkylene glycol such as polyethylene glycol is used.
- enteric polymer examples include: hydroxyalkyl cellulose phthalate such as hydroxypropylmethyl cellulose phthalate; hydroxyalkyl cellulose acetate succinate such as hydroxypropylmethyl senorelose acetate succinate; carboxymethylethyl cellulose; Carboxyalkyl cellulose; cellulose acetate phthalate; methacrylic acid copolymer L—100-5 Copolymers of ethyl acrylate and methacrylic acid such as 5; copolymers of methyl methacrylate and methacrylic acid such as methacrylic acid copolymer L and methacrylic acid copolymer S are used.
- gastric-soluble polymer for example, aminoalkyl methacrylate copolymer E; polybutylacetal getylaminoacetate and the like are used.
- copolymers containing a small amount of quaternary ammonium groups of ethyl acrylate and methyl methacrylate such as methacrylic acid copolymer RL and methacrylic acid copolymer RS, carboxymethylcellulose, carboxyviel polymer, poly Hydrophilic polymers that can disperse poorly water-soluble or insoluble lipids, litchi, plaque regression substances such as BURU alcohol, acacia, sodium alginate, propylene glycol alginate, agar, gelatin, and chitosan are used.
- hydrophilic polymers may be used as a mixture of two or more kinds.
- hydrophilic polymer hydroxyalkylcellulose, alkynolecellulose, polyalkenylpyrrolidone, polyalkylene glycol, methacrylic acid copolymer, carboxymethylcellulose and the like are preferable, and hydroxypropinolemethinoresenolerose is particularly preferable.
- Preferred are phthalate, polyvinylpyrrolidone, hydroxypropylmethylcellulose, canoleboxymethylethylsenorelose, and methacrylic acid copolymer L.
- the solid dispersion may contain additives generally used in the field of pharmaceutical formulation.
- compositions such as various organic and inorganic carrier substances commonly used as pharmaceutical materials are used as excipients. Excipients, lubricants, binders, disintegrants, surfactants 1 ⁇ It is compounded as a crude drug. If necessary, pharmaceutical additives such as preservatives, antioxidants, coloring agents and sweeteners can also be used.
- shell molds include, for example, milk bran, shirasu, D-mannitol, starch, crystalline cenorelose, sucrose, perforated starch, man-tol, silicate acid (trade name: Flow) Light RE), magnesium metasilicate aluminate (Trade Product name: Neusilin), Light caffeic anhydride (trade name: Silisha), White sugar
- Spherical granules product name: non-pareil
- crystalline cellulose product name: crystalline cellulose 'carboxymethylcellulose
- lubricant examples include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- binder examples include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, and polybutylpyrrolidone.
- Preferred examples of the disintegrant include starch, carboxymethylcellulose, carboxymethylcellulose canolesum, cross force / remelose sodium, carboxymethyl starch sodium, methylcellulose (trade name: Metrose SM), cloth Potato noremelose sodium, canolemellose kanoresum, low-substituted hydroxypropylcellulose, sodium starch glycolate, partially pre-alpha starch, etc. are used.
- lubricant for example, tark / lek, crystalline cellulose, magnesium stearate, corn starch, magnesium acid salt and the like are used.
- surfactant examples include polyoxyethylene polyoxypropylene glycol (trade name: Pull Mouth Nick), glycerin fatty acid ester, sucrose fatty acid ester, polyoxyethylene hydrogenated castor oil, polysorbate 80, cetanol, and the like. Used.
- Preferred examples of the preservative include, for example, paraoxybenzoic acid esters, butanol, benzothreanolone, phenethyl alcohol, dehydroacetic acid, and sorbic acid.
- Suitable examples of the antioxidant include, for example, sulfite, ascorbic acid and the like.
- the solid dispersion can be produced by a method known per se, and specifically, for example, a solvent method such as a spray drying method or a rotary evaporation method; It can be produced by a melting method such as an extruder method; a mixed powder frame method; an ultrasonic method using an ultrasonic molding machine or the like.
- a solvent method such as a spray drying method or a rotary evaporation method
- It can be produced by a melting method such as an extruder method; a mixed powder frame method; an ultrasonic method using an ultrasonic molding machine or the like.
- the solid dispersion can be produced by the following solvent method.
- suspending additives such as excipients, disintegrants, lubricants and surfactants in this suspension or solution;
- the organic solvent is distilled off from the homogeneous suspension under reduced pressure or normal pressure by a conventional method, for example, a spray drying method or a rotary evaporation method.
- a homogeneous suspension is prepared in the above step (2), and then sequentially subjected to the following steps.
- the organic solvent is distilled off under reduced pressure or normal pressure by a conventional method, for example, a spray drying method or a rotary evaporation method.
- the organic solvent used in the above step (1) is not particularly limited as long as it is capable of dissolving a poorly water-soluble or insoluble lipid, litsch, plaque regression substance and a hydrophilic polymer, and examples thereof include methanol and ethanol.
- Aliphatic hydrocarbons such as 1-hexane, cyclohexane, and n-heptane: Aromatic hydrocarbons such as benzene, toluene, and xylene: nitriles such as acetonitrile; organic acids such as acetic acid and propionic acid ; Ethyl acetate, etc.
- Esters aliphatic halogenated hydrocarbons such as dichloromethane, dichloroethane, and chloroform; ketones such as acetone and methyl ketone; dimethylformamide, dimethyla Amides such as cetamide; or a mixture thereof at an appropriate ratio is used.
- low-boiling solvents such as ketones and alcohols are preferable, and among them, acetone, ethanol and the like are preferable.
- the operating conditions such as the processing temperature and the processing time vary depending on the used starting compounds, organic solvents, and the like, but the processing temperature is usually 200 ° C. or lower.
- a water-insoluble or insoluble lipid 'ritsch plaque regression substance is heated to a temperature higher than the melting point and melted, and then a hydrophilic polymer, as required, an excipient, a disintegrant, a lubricant and the like are used. It can be manufactured by dissolving an additive such as a surfactant in this and quenching.
- poorly water-soluble or insoluble lipids such as lipid plaque regression substances and hydrophilic polymers, if necessary, such as excipients, disintegrants, lubricants and surfactants It can be produced by heating a mixture of additives physically, under high pressure, to melt the hardly soluble or insoluble lipid-rich 'plaque regression substance at a temperature below the melting point, and then quenching it.
- a poorly water-soluble or insoluble lipid 'rich plaque regression substance and a hydrophilic polymer and if necessary, additives such as excipients, disintegrants, lubricants and surfactants were physically mixed. It can be manufactured by mixing and milling.
- ultrasonic method physical mixing of poorly water-soluble or insoluble lipid 'rich' plaque retraction material and hydrophilic polymer, and additives such as excipients, disintegrants, lubricants and surfactants as necessary
- the resulting material can be filled in a die, preformed, and then irradiated with ultrasonic waves, for example, using an ultrasonic molding machine, to produce the product.
- the amount of the hydrophilic polymer is not particularly limited, and may be any amount as long as it is capable of dispersing the poorly water-soluble or insoluble lipid / rich / plaque regression substance.
- a suitable weight ratio of the hydrophilic polymer to the poorly water soluble or insoluble lipid 'rich' plaque regression substance may be in the range of 0.01: 1 to 100: 1, preferably 0: 1. 0.2: 1 to 50: 1, more preferably 0.1: 2 to 20: 1, even more preferably 0.3: 1 to 10: 1, more preferably 1: 1 to 10: 1. : 1 in Yes, especially 3-5 (especially 4): 1 is preferred.
- the amount of the additive is not particularly limited, but when the additive is used, the additive such as S warp, disintegrator, Hitoshi Luzawa, surfactant, etc. is hardly water-soluble or insoluble lipid-rich plaque regression
- a suitable weight ratio with the substance may be generally in the range of 0.1: 1 force, such as 20: 1, preferably in the range of 0.3: 1 to 10: 1, more preferably in the range of 1: 1 to 3: Is one.
- the organic solvent used in the above step (5) is not particularly limited, and any solvent may be used as long as it can dissolve the suspension of the above step (2), such as chloroform and dichloromethane.
- the solid dispersion itself can be used as a pharmaceutical preparation for oral administration itself, and can also be made into a pharmaceutical preparation such as fine granules, fine granules, granules, tablets, capsules, and injections by a conventional method.
- the pharmaceutical preparation containing the solid dispersion may be, if desired, the above-mentioned additive, specifically, a coloring agent, a sweetening agent, a fragrance such as sucrose, lactose, starch, crystalline cellulose, synthetic cake, and the like.
- a coloring agent such as sucrose, lactose, starch, crystalline cellulose, synthetic cake, and the like.
- Ammonium acid, magnesium stearate, talc and other diluents and lubricants may be mixed with pharmaceutical preparations for oral administration.
- a sustained-release preparation can be prepared by coating the preparation surface.
- lipid 'litchi plaque regression substances are poorly water-soluble or insoluble, and when administered orally, have a low bioavailability due to the fact that only a small percentage of the dose is actually absorbed into the blood. have.
- the solid dispersion achieves solubilization of a poorly water-soluble or insoluble lipid'-rich plaque regression substance, whereby a poorly water-soluble, low-soluble lipid'-rich 'plaque retraction substance is obtained.
- Availability is dramatically improved.
- the content of the sparingly water-soluble or water-insoluble lipid 'rich' plaque-reducing substance in the solid dispersion varies depending on the dosage form, administration method, carrier, etc., but is usually 0.1 to 99% (w / w).
- the content of the hydrophilic polymer in the solid dispersion varies depending on the dosage form, administration method, carrier and the like, but is usually 1 to 99.9% (w / w) based on the total amount of the preparation.
- the content of the additive in the solid dispersion is usually 0 to 99% (w / w) based on the total amount of the preparation, which varies depending on the dosage form, administration method, and the like.
- the content of the solid dispersion in the pharmaceutical preparation of the present invention varies depending on the dosage form, administration method, carrier and the like, but is usually 1 to: L O O% (w / w) based on the total amount of the preparation.
- the content of the additive in the pharmaceutical preparation of the present invention varies depending on the dosage form, administration method and the like, but is usually 0 to 99.9% (w / w) based on the total amount of the preparation.
- the dose of the concomitant drug of the present invention varies depending on the type, age, body weight, symptom, dosage form, administration method, administration period, and the like of the compound of the present invention.
- a hyperlipidemic patient adult, weight of about 60 kg
- Per person usually about 0.01 to about 100 mg / kg, preferably about 0.01 to about 10 Omg / kg, more preferably about 0.1 to about 100 mg / kg each day as the compound of the present invention.
- the dose varies under various conditions, so that a smaller dose may be sufficient in some cases, or it may be necessary to administer a dose outside the range.
- the concomitant drug can be used in any amount as long as side effects are not a problem.
- the daily dosage of the concomitant drug varies depending on the severity of symptoms, age, gender, body weight, difference in sensitivity, administration timing, interval, characteristics of pharmaceutical preparation, preparation, type, type of active ingredient, etc.
- the amount of the drug is usually about 0.001 to 2000 mg, preferably about 0.01 to 500 mg, more preferably about 0.1 to 10 Omg per kg body weight of a mammal by oral administration. This is usually administered once to four times a day.
- the concomitant drug may be administered at the same time, but the concomitant drug may be administered first, and then the compound of the present invention may be administered, or the compound of the present invention may be administered first. And then the concomitant drug may be administered.
- the time difference depends on the active ingredient to be administered, dosage form, and administration method.
- a concomitant drug is administered first, within 1 minute to 3 days after administration of the concomitant drug, preferably The method includes administering the compound of the present invention within 10 minutes to 1 day, more preferably within 15 minutes to 1 hour.
- the concomitant drug is administered within 1 minute to 1 day, preferably within 10 minutes to 6 hours, more preferably within 15 minutes to 1 hour after administration of the compound of the present invention.
- the method of administration is mentioned.
- a concomitant drug formed into an oral administration preparation is orally administered, and after about 15 minutes, the drug of the present invention is formed into an oral administration preparation.
- Daggered product About 0.005 ⁇ : L 0 OmgZkg is orally administered as a daily dose.
- the iHNMR spectrum was measured with a Varian Diemi-200 (200 MHz) type spectrometer using tetramethylsilane as an internal standard, and the total ⁇ value was shown in ppm.
- the reaction solution was concentrated under reduced pressure, and the obtained residue was dissolved in a mixed solvent of THF (10 ml) and ethyl acetate (50 ml), and then water, a saturated aqueous solution of sodium hydrogen carbonate and saturated sodium chloride were added. Washing was sequentially performed with an aqueous solution. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by recrystallization from ethyl acetate to obtain the title compound (0.52 g, yield 62%).
- N-Bromosuccinic acid imidate 50 ml was added to a solution of ethyl acetate (3.5 g) in ethyl acetate (50 ml) (7-methyl alcohol 6-methinole 2-oxo-41-phenylenol 2H-chromen-3-yl).
- 2.1 g and 2,2'-azoisobutyronitrile 48.3 mg were added, and the mixture was heated under reflux for 1 hour. After cooling, the reaction solution was washed successively with water, a saturated aqueous solution of sodium hydrogencarbonate and a saturated aqueous solution of sodium chloride.
- the reaction solution is concentrated under reduced pressure, and the obtained residue is dissolved in a mixed solvent of THF (10 ml) and ethyl acetate (50 ml), and then successively with water, a saturated aqueous solution of sodium hydrogencarbonate and an aqueous solution of saturated sodium salt of sodium chloride. Washed. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was washed with ethyl acetate to obtain crude crystals of the title compound (1.78 g, yield 44%). This compound was used for the next reaction without further purification.
- the extract was washed successively with 1 N hydrochloric acid, a saturated aqueous sodium chloride solution, a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure.
- the obtained residue was dissolved in THF (2 ml), morpholine (0.21 ml) was added, and the mixture was stirred for 3 days.
- the reaction solution was concentrated under reduced pressure, and the obtained residue was dissolved in ethyl acetate (30 ml) and washed with a saturated sodium chloride aqueous solution. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure.
- the extract was washed successively with 1 N hydrochloric acid, a saturated aqueous solution of sodium chloride, a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure.
- the obtained residue was dissolved in DMF (2 ml), anhydrous sodium acetate (150 mg) was added, and the mixture was stirred at 60 ° C for 3 hours. Water was added to the reaction solution, the product was extracted with ethyl acetate, and the extract was washed with a saturated sodium chloride aqueous solution. After drying over magnesium sulfate, the solvent was distilled off under reduced pressure, and the obtained residue was purified by recrystallization from THF to give the title compound (61 mg, yield 36%).
- the extract was washed successively with 1N hydrochloric acid, a saturated aqueous sodium chloride solution, a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution, dried over magnesium sulfate, and then the solvent was distilled off under reduced pressure. .
- the obtained residue was dissolved in DMF (3 ml), anhydrous sodium acetate (121 mg) was added, and the mixture was stirred at 60 ° C for 3 hours. Water was added to the reaction mixture, the product was extracted with ethyl acetate, and the extract was washed with a saturated aqueous sodium chloride solution.
- Acetic acid [7-chloro-3- (2- (2-chloro-4-trifluoromethylarinino) -2-oxoethyl) -2-oxo-4-phenyl-2-H-octene- 6-yl] methyl ester (81 rag) was dissolved in a mixed solvent of THF (0.4 ml) and methanol (2 ml), DBU (0.11 ml) was added, and the mixture was stirred at room temperature for 30 minutes. did. The reaction mixture was diluted with ethyl acetate (30 ml), diluted with 1N hydrochloric acid, saturated aqueous sodium chloride, and saturated aqueous sodium hydrogen carbonate.
- the solution was washed successively with a liquid and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure.
- the obtained residue was purified by silica gel gel ram chromatography (developing solvent: ethyl acetate), and further purified by recrystallization from ethyl acetate to obtain the title compound (34 mg, yield 80%).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020037000520A KR100866820B1 (ko) | 2000-07-13 | 2001-07-13 | 지질 풍부 플라크 퇴축제 |
PL36039801A PL360398A1 (en) | 2000-07-13 | 2001-07-13 | Lipid-rich plaque inhibitors |
AU6951601A AU6951601A (en) | 2000-07-13 | 2001-07-13 | Lipid-rich plaque inhibitors |
AU2001269516A AU2001269516B2 (en) | 2000-07-13 | 2001-07-13 | Lipid-rich plaque regressing agents |
EP01947999A EP1302470A4 (en) | 2000-07-13 | 2001-07-13 | INHIBITORS OF PLATES RICH IN LIPID |
US10/332,632 US6974806B2 (en) | 2000-07-13 | 2001-07-13 | Lipid-rich plaque inhibitors |
HU0302825A HUP0302825A3 (en) | 2000-07-13 | 2001-07-13 | Lipid-rich plaque inhibitors |
CA002429008A CA2429008A1 (en) | 2000-07-13 | 2001-07-13 | Lipid-rich plaque regressing agents |
IL15363301A IL153633A0 (en) | 2000-07-13 | 2001-07-13 | Lipid-rich plaque inhibitors |
NZ523550A NZ523550A (en) | 2000-07-13 | 2001-07-13 | Lipid-rich plaque inhibitors |
NO20030138A NO20030138D0 (no) | 2000-07-13 | 2003-01-10 | Lipidrikt plakkinnkapslende middel |
US11/212,800 US20060035865A1 (en) | 2000-07-13 | 2005-08-26 | Lipid-rich plaque regressing agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-212611 | 2000-07-13 | ||
JP2000212611 | 2000-07-13 | ||
JP2000-395079 | 2000-12-26 | ||
JP2000395079 | 2000-12-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/212,800 Division US20060035865A1 (en) | 2000-07-13 | 2005-08-26 | Lipid-rich plaque regressing agents |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002006264A1 true WO2002006264A1 (fr) | 2002-01-24 |
Family
ID=26595951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/006070 WO2002006264A1 (fr) | 2000-07-13 | 2001-07-13 | Inhibiteurs de plaques riches en lipide |
Country Status (12)
Country | Link |
---|---|
US (2) | US6974806B2 (ja) |
EP (1) | EP1302470A4 (ja) |
KR (1) | KR100866820B1 (ja) |
CN (1) | CN1441794A (ja) |
AU (2) | AU2001269516B2 (ja) |
CA (1) | CA2429008A1 (ja) |
HU (1) | HUP0302825A3 (ja) |
IL (1) | IL153633A0 (ja) |
NO (1) | NO20030138D0 (ja) |
NZ (1) | NZ523550A (ja) |
PL (1) | PL360398A1 (ja) |
WO (1) | WO2002006264A1 (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002047723A1 (fr) * | 2000-12-11 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Compositions medicamenteuses presentant une meilleure hydrosolubilite |
US6509362B2 (en) * | 1997-12-23 | 2003-01-21 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them |
WO2002094799A3 (en) * | 2001-05-22 | 2003-11-06 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
EP1935885A3 (en) * | 2001-05-22 | 2008-10-15 | Neurogen Corporation | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. |
WO2008143262A1 (ja) | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
WO2009123316A1 (ja) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
EP2119715A1 (en) | 2004-02-25 | 2009-11-18 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and its use as aii receptor antagonist |
US7709476B2 (en) * | 2003-09-23 | 2010-05-04 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
WO2010087467A1 (en) | 2009-01-27 | 2010-08-05 | Takeda Pharmaceutical Company Limited | Delta-5-desaturase inhibitors |
EP2256115A1 (en) | 2006-11-24 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound and use thereof |
WO2012011591A1 (ja) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8513282B2 (en) | 2008-10-23 | 2013-08-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2014030743A1 (ja) | 2012-08-24 | 2014-02-27 | 武田薬品工業株式会社 | 複素環化合物 |
US9670163B2 (en) | 2005-12-28 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ523550A (en) * | 2000-07-13 | 2004-05-28 | Takeda Chemical Industries Ltd | Lipid-rich plaque inhibitors |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US20040019096A1 (en) * | 2001-10-23 | 2004-01-29 | Vlassios Andronis | Novel formulations of carvedilol |
WO2003059900A1 (fr) * | 2002-01-11 | 2003-07-24 | Takeda Chemical Industries, Ltd. | Derives de coumarine, leur procede de production et d'utilisation |
AU2004267972B2 (en) * | 2003-08-29 | 2010-07-08 | Kowa Co., Ltd. | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
AU2005217335A1 (en) * | 2004-03-02 | 2005-09-09 | Takeda Pharmaceutical Company Limited | Coumarin derivative and use thereof |
AT500144A1 (de) * | 2004-03-05 | 2005-11-15 | Sanochemia Pharmazeutika Ag | Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung |
CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
WO2006002421A2 (en) * | 2004-06-24 | 2006-01-05 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
TW200619204A (en) * | 2004-12-10 | 2006-06-16 | Kowa Co | Method for reduction, stabilization and prevention of rupture of lipid rich plaque |
AR055041A1 (es) * | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
US7772255B2 (en) * | 2005-12-13 | 2010-08-10 | Supratek Pharma, Inc. | Method of treating tumors with azaxanthones |
CA2634113A1 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
JP5291979B2 (ja) * | 2008-04-24 | 2013-09-18 | 株式会社フジクラ | 圧力センサ及びその製造方法と、該圧力センサを備えた電子部品 |
CA2756031C (en) | 2009-03-20 | 2018-01-02 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
US20210177842A1 (en) * | 2019-10-23 | 2021-06-17 | Piedmont Animal Health Inc. | Pimobendan formulation and method of use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6471817A (en) * | 1987-08-26 | 1989-03-16 | Pfizer | Medicinal composition for antiatherosclerotic |
JPH06340647A (ja) * | 1993-02-27 | 1994-12-13 | Nippon Nohyaku Co Ltd | N−ヘテロアリール−n′−フェニル尿素誘導体,その製法及びその用途 |
JPH07149722A (ja) * | 1992-12-16 | 1995-06-13 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE161530T1 (de) * | 1992-09-04 | 1998-01-15 | Takeda Chemical Industries Ltd | Kondensierte heterozyklische verbindungen, deren herstellung und verwendung |
TW234123B (ja) | 1992-12-16 | 1994-11-11 | Takeda Pharm Industry Co Ltd | |
JP3524133B2 (ja) | 1993-01-14 | 2004-05-10 | 武田薬品工業株式会社 | 含窒素縮合複素環化合物、その製造法及び剤 |
JPH08295667A (ja) | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
NZ523550A (en) * | 2000-07-13 | 2004-05-28 | Takeda Chemical Industries Ltd | Lipid-rich plaque inhibitors |
-
2001
- 2001-07-13 NZ NZ523550A patent/NZ523550A/en unknown
- 2001-07-13 CN CN01812691A patent/CN1441794A/zh active Pending
- 2001-07-13 EP EP01947999A patent/EP1302470A4/en not_active Withdrawn
- 2001-07-13 KR KR1020037000520A patent/KR100866820B1/ko not_active IP Right Cessation
- 2001-07-13 CA CA002429008A patent/CA2429008A1/en not_active Abandoned
- 2001-07-13 HU HU0302825A patent/HUP0302825A3/hu unknown
- 2001-07-13 WO PCT/JP2001/006070 patent/WO2002006264A1/ja active IP Right Grant
- 2001-07-13 IL IL15363301A patent/IL153633A0/xx unknown
- 2001-07-13 AU AU2001269516A patent/AU2001269516B2/en not_active Ceased
- 2001-07-13 AU AU6951601A patent/AU6951601A/xx active Pending
- 2001-07-13 US US10/332,632 patent/US6974806B2/en not_active Expired - Fee Related
- 2001-07-13 PL PL36039801A patent/PL360398A1/xx not_active Application Discontinuation
-
2003
- 2003-01-10 NO NO20030138A patent/NO20030138D0/no not_active Application Discontinuation
-
2005
- 2005-08-26 US US11/212,800 patent/US20060035865A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6471817A (en) * | 1987-08-26 | 1989-03-16 | Pfizer | Medicinal composition for antiatherosclerotic |
JPH07149722A (ja) * | 1992-12-16 | 1995-06-13 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および剤 |
JPH06340647A (ja) * | 1993-02-27 | 1994-12-13 | Nippon Nohyaku Co Ltd | N−ヘテロアリール−n′−フェニル尿素誘導体,その製法及びその用途 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1302470A4 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6509362B2 (en) * | 1997-12-23 | 2003-01-21 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them |
WO2002047723A1 (fr) * | 2000-12-11 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Compositions medicamenteuses presentant une meilleure hydrosolubilite |
WO2002094799A3 (en) * | 2001-05-22 | 2003-11-06 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
EP1935885A3 (en) * | 2001-05-22 | 2008-10-15 | Neurogen Corporation | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. |
US7709476B2 (en) * | 2003-09-23 | 2010-05-04 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
EP2119715A1 (en) | 2004-02-25 | 2009-11-18 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and its use as aii receptor antagonist |
US9670163B2 (en) | 2005-12-28 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2256115A1 (en) | 2006-11-24 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound and use thereof |
WO2008143262A1 (ja) | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
EP2253630A1 (en) | 2007-05-21 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
WO2009123316A1 (ja) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8513282B2 (en) | 2008-10-23 | 2013-08-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8598205B2 (en) | 2008-10-23 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8604203B2 (en) | 2008-10-23 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8785640B2 (en) | 2008-10-23 | 2014-07-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8969382B2 (en) | 2008-10-23 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2010087467A1 (en) | 2009-01-27 | 2010-08-05 | Takeda Pharmaceutical Company Limited | Delta-5-desaturase inhibitors |
WO2012011591A1 (ja) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
WO2014030743A1 (ja) | 2012-08-24 | 2014-02-27 | 武田薬品工業株式会社 | 複素環化合物 |
US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
Also Published As
Publication number | Publication date |
---|---|
CA2429008A1 (en) | 2003-01-09 |
KR20030015390A (ko) | 2003-02-20 |
EP1302470A1 (en) | 2003-04-16 |
US6974806B2 (en) | 2005-12-13 |
US20060035865A1 (en) | 2006-02-16 |
US20030232809A1 (en) | 2003-12-18 |
AU2001269516B2 (en) | 2006-09-14 |
HUP0302825A3 (en) | 2005-02-28 |
PL360398A1 (en) | 2004-09-06 |
NO20030138L (no) | 2003-01-10 |
NO20030138D0 (no) | 2003-01-10 |
EP1302470A4 (en) | 2005-04-06 |
NZ523550A (en) | 2004-05-28 |
IL153633A0 (en) | 2003-07-06 |
CN1441794A (zh) | 2003-09-10 |
KR100866820B1 (ko) | 2008-11-04 |
AU6951601A (en) | 2002-01-30 |
HUP0302825A2 (hu) | 2003-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002006264A1 (fr) | Inhibiteurs de plaques riches en lipide | |
JP6689297B2 (ja) | 複素環化合物 | |
US20070179154A1 (en) | Coumarin derivatives, process for their production and use thereof | |
AU2015285142B2 (en) | Heterocyclic compounds and their use as Retinoid-related orphan receptor (ROR) gamma-T inhibitors | |
WO2011007819A1 (ja) | ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬 | |
CN1984905B (zh) | 作为凝血酶受体拮抗剂的约束喜巴辛类似物 | |
WO2017038909A1 (en) | Heterocyclic compounds | |
WO2016021742A1 (en) | Heterocyclic compounds as ep4 receptor antagonists | |
JPWO2017033946A1 (ja) | 複素環化合物 | |
CN104918936A (zh) | 作为细胞凋亡信号调节激酶抑制剂的经取代的吡啶-2-甲酰胺化合物 | |
EA032201B1 (ru) | Конденсированные гетероциклические соединения | |
CN101646653A (zh) | 作为ppar-y的部分激动剂的稠环化合物 | |
CN106879256B (zh) | 2-氨基-苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素e合成酶抑制剂的应用 | |
WO2016088903A1 (en) | Heterocyclic compounds | |
DE60307804T2 (de) | Pyranon- und pyrandioninhibitoren der rna-abhängigen rna-polymerase des hepatitis-c-virus | |
TW201341377A (zh) | 作為par-受體拮抗劑之雙環喜巴辛(himbacine)衍生物之製備及用途 | |
WO2020027225A1 (ja) | 複素環化合物 | |
JP2002255808A (ja) | リピド・リッチ・プラーク退縮剤 | |
KR20060130189A (ko) | 쿠마린 유도체 및 그의 용도 | |
EP1460062A1 (en) | Nitrogenous cyclic ketone derivative, process for producing the same, and use | |
JP2002241267A (ja) | 水溶解性が改善された医薬組成物 | |
JP2003267965A (ja) | クマリン誘導体、その製法および用途 | |
NZ546284A (en) | Coumarin derivatives, process for their production and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 153633 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001269516 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2429008 Country of ref document: CA Ref document number: 523550 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10332632 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037000520 Country of ref document: KR Ref document number: 01812691X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001947999 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037000520 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001947999 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Country of ref document: RU Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 523550 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 523550 Country of ref document: NZ |